Document:

<PAGE>
                                                                  EXHIBIT 10(ac)

                      TERMINATION OF SERVICE AGREEMENT AND
                    AGREEMENT FOR PURCHASE AND SALE OF ASSETS

        This Termination of Service Agreement and Agreement for Purchase and
Sale of Assets ("AGREEMENT") is made as of the 31st day of January, 2001, by and
between RESPONSE ONCOLOGY, INC., a Tennessee corporation ("RESPONSE") and
ONCOLOGY HEMATOLOGY GROUP OF SOUTH FLORIDA, P.A., a Florida professional service
corporation ("ONCOLOGY").

                                    RECITALS:

        WHEREAS, Response and Oncology entered into a Service Agreement dated
January 2, 1996, as amended February 25, 1997 ("1ST AMENDMENT"), August 15, 1997
("2ND AMENDMENT") and July 20, 1999 ("3RD AMENDMENT") (collectively, the
"SERVICE AGREEMENT"), pursuant to which Response agreed to perform certain
practice management functions described therein in exchange for payment by
Oncology to Response of various fees, as described therein; and

        WHEREAS, Oncology desires to decrease its operating expenses; and

        WHEREAS, the parties mutually desire to terminate the Service Agreement
and all of the parties' respective obligations and liabilities thereunder
(except as otherwise provided herein), and to provide for the transfer and/or
assumption of certain assets and liabilities, all upon the terms and conditions
hereinafter set forth;

        NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, the purchase price described hereunder and other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties, intending to be legally bound, hereby agree as
follows:

        1. Recitals. The recitals set forth above are true and correct and are
incorporated herein by reference.

        2. Termination of Service Agreement.

           (a) Subject to the performance by each of the parties of their
respective obligations under this Agreement, and the survival of any obligations
which by the terms of this Agreement are intended to survive, the parties hereby
terminate the Service Agreement effective as of the Closing Date (as hereinafter
defined). In addition to the other transactions described herein, as
consideration for the termination of the Service Agreement which Oncology
believes will significantly reduce the operating expenses, and the mutual
release of the parties from their respective obligations thereunder, Oncology
shall pay to Response at Closing via cashier's or attorney's trust account check
or wire transfer Three Million Four Hundred Ninety-Eight Thousand Dollars and
00/100 ($3,498,000.00) (the "TERMINATION FEE") (based upon EBITDA of
$1,479,200.00), subject to adjustments, prorations, credits and setoffs
hereinafter described.

           (b) It is the parties' intent that the Termination Fee shall be an
amount equal to 2.5 times EBITDA (including all ancillary and professional
departments of Oncology) for the calendar

                                       1
<PAGE>

year 2000, as EBITDA is customarily reported on the Response/Oncology Statement
of Operations, based on accounting principles consistently applied with prior
practice, less Two Hundred Thousand Dollars ($200,000.00) (the "FORMULA
TERMINATION FEE"). In the event the calendar year 2000 EBITDA has not been
determined as of the Closing Date (as hereinafter defined), an appropriate
adjusting payment shall be made within thirty (30) days after the Closing Date
by Oncology to Response if the Formula Termination Fee exceeds the Termination
Fee or by Response to Oncology if the Formula Termination Fee is less than the
Termination Fee. The parties both acknowledge and agree to the EBITDA figure as
it is reflected on the Response/Oncology Statement of Operations dated as of
December 31, 2000, which is attached hereto as EXHIBIT 2.

        3. [REPAYMENT OF RESPONSE NOTES AND TERMINATION OF STOCK OPTIONS.
ONCOLOGY SHALL RECEIVE AS A CREDIT AGAINST THE TERMINATION FEE, AN AMOUNT EQUAL
TO THE OUTSTANDING PRINCIPAL AND INTEREST BALANCE OF THOSE CERTAIN PROMISSORY
NOTES WITH AN AGGREGATE ORIGINAL PRINCIPAL AMOUNT OF ONE MILLION EIGHT HUNDRED
TEN THOUSAND FIVE HUNDRED EIGHT DOLLARS AND 70/100 ($1,810,508.70) FROM RESPONSE
TO THE SHAREHOLDERS OF ONCOLOGY, WHICH ARE ATTACHED AS EXHIBIT 3(I) HERETO (THE
"RESPONSE NOTES"). THE PARTIES AGREE THAT THE AMOUNT NECESSARY TO SATISFY THE
RESPONSE NOTES IN FULL AS OF THE CLOSING DATE IS SEVEN HUNDRED FORTY-ONE
THOUSAND DOLLARS AND 00/100 ($741,000.00). ONCOLOGY SHALL RECEIVE A FURTHER
CREDIT AGAINST THE TERMINATION FEE IN THE AMOUNT OF TEN THOUSAND DOLLARS
($10,000.00) WHICH THE PARTIES AGREE IS EQUAL TO THE VALUE OF THOSE CERTAIN
STOCK OPTIONS IN FAVOR OF ONCOLOGY'S STOCKHOLDERS, AS DESCRIBED AND AS LISTED IN
EXHIBIT 3(II) HERETO AND INCORPORATED HEREIN (THE "RESPONSE STOCK OPTIONS").
ONCOLOGY SHALL CAUSE ITS SHAREHOLDERS TO SATISFY AND CANCEL THE RESPONSE NOTES
AND DELIVER SAME TO RESPONSE. ONCOLOGY SHALL FURTHER CAUSE ITS SHAREHOLDERS TO
TERMINATE ALL OF THE RESPONSE STOCK OPTIONS AT CLOSING SUCH THAT THE RESPONSE
STOCK OPTIONS ARE OF NO FURTHER FORCE OR EFFECT.]

        4. Accounts Receivable Credit Line. Pursuant to paragraph 5 of the 2nd
Amendment to the Service Agreement, Response established an accounts receivable
line of credit (the "RECEIVABLES LINE" as described therein), constituting a
line of credit available to Oncology and secured by a first priority security
interest in and to all Accounts Receivable (as defined in the Service
Agreement). As of the date hereof (the "EFFECTIVE DATE" or the "CLOSING DATE")
the Receivables Line is Six Million Six Hundred and Sixty Five Thousand Dollars
($6,665,000.00). A listing of the Medicare, Medicaid, and CHAMPUS/TriCare
program receivables is set forth on EXHIBIT 4-1 (the "MEDICARE ACCOUNTS
RECEIVABLE"). A listing of all Accounts Receivable other than the Medicare
Accounts Receivable is set forth on EXHIBIT 4-2 (the "NON-MEDICARE ACCOUNTS
RECEIVABLE"). On the Closing Date, Oncology shall assign all of its rights,
title, and interest in and to the Non-Medicare Accounts Receivable to Response.
Oncology hereby assigns to Response a first priority security interest, to be
evidenced by a Security Agreement in the form attached hereto as EXHIBIT 4-3, in
and to the proceeds of the Medicare Accounts Receivable and hereby agrees that
it shall pay out an amount equal to the amount of such proceeds to Response on a
continuing basis. The parties agree to amend EXHIBITS 4-1 AND 4-2 to more
accurately reflect the actual accounts receivable within twenty (20) days after
Closing. The following provisions shall also apply with respect to the
assignment of the Non-Medicare Accounts Receivable, the security interest in the
proceeds of the Medicare Accounts Receivable and the satisfaction of the
Receivables Line:

                                       2
<PAGE>

           (a) To assist Response in collecting the Accounts Receivable,
Oncology will promptly cooperate and assist in such collection efforts as
reasonably requested by Response, in a manner consistent with prior practice. In
regard to both Non-Medicare Accounts Receivable and Medicare Accounts
Receivable, Oncology shall receive collections on account of said Accounts
Receivable and pay an amount equal to all amounts actually collected to Response
on a weekly basis. Oncology shall allow an employee or agent of Response to be
on-site at Oncology's billing and collections office and to have full access to
review, copy and transmit all incoming payments, explanations of benefits, and
other correspondence and documents relating to the collection of the Accounts
Receivable. In addition, said employee shall have "read only" access to
Oncology's medical billing information system for dates of service subsequent to
the Closing Date. The parties acknowledge and agree that in the event the
aforesaid procedure in regard to payments on account of the Medicare Accounts
Receivable are not permitted under applicable laws, rules, or regulations
affecting same, then the parties shall use such other reasonable means to effect
substantially the same results.

           (b) The parties agree and acknowledge that the assignment of Accounts
Receivable pursuant to this SECTION 4 shall constitute satisfaction in full of
the Receivables Line, notwithstanding the amount or success of actual
collectability of the Accounts Receivables by Response or any other party.
Response shall deliver such releases of the Receivables Line, as may be
necessary to satisfy all liability of Oncology and/or its principals under the
Receivables Line and to release Oncology's Accounts Receivable arising after the
Closing Date from any liens, including, but not limited to, UCC-3 amendments to
financing statements, limiting the lien of Response and/or any other party
claiming by or through Response to the Accounts Receivable, to the actual
Accounts Receivable as of the Closing Date. Response shall indemnify Oncology
and hold it harmless against any and all claims, losses, liabilities and damages
incurred by Oncology as a result of the failure of Response to obtain such
releases of the Receivables Line and the release of liens, if any, on Oncology's
Accounts Receivable created after the Closing Date.

           (c) As a condition precedent to Oncology's and to Response's
obligation to close hereunder, in addition to such releases, and other documents
and instruments required by Oncology pursuant to SECTION 4(B) hereunder,
Oncology shall have received a statement in the form of EXHIBIT 4(C) attached
hereto and incorporated herein by reference, executed by AmSouth, Response's
lead lender for the Receivables Line ("RESPONSE ACCOUNTS RECEIVABLE LOAN"), on
its own behalf and on behalf of all other lenders who have participated in the
Response Accounts Receivable Loan, stating each of the following:

                (i)     it has received and reviewed this Agreement;

                (ii)    it has reviewed the terms and provisions of this
                        Termination Agreement with counsel of its choosing and
                        has accepted the same as being fair and reasonable and
                        that the property tendered by Response to Oncology is a
                        fair and reasonably equivalent value for the
                        consideration being paid to Response by Oncology;

                (iii)   subject to assignment of the Non-Medicare Accounts
                        Receivable and grant by Oncology of a first priority
                        security interest in the Medicare

                                       3
<PAGE>

                        Accounts Receivable, it releases any claims against
                        Oncology and Oncology's Representatives (as defined in
                        SECTION 10(A) below) and all liens or encumbrances
                        against the assets of Oncology other than the Accounts
                        Receivable arising prior to the Closing Date;

                (iv)    it acknowledges that the Amsouth acknowledgment and
                        estoppel letter shall constitute a release of all liens
                        and encumbrances against the assets of Oncology other
                        than the Accounts Receivable arising prior to the
                        Closing Date; and

                (v)     its commitment to execute and deliver such releases,
                        satisfactions, and termination statements, as shall be
                        necessary to release or discharge any liens against
                        Oncology's assets created or arising in connection with
                        the Response receivables loan that relate to the
                        Accounts Receivable arising after the Closing Date.

           (d) [WITH RESPECT TO ALL ACCOUNTS RECEIVABLE ARISING FROM THE
RADIATION THERAPY PROFIT CENTER (AS DEFINED IN THE "SERVICE AGREEMENT") AS
LISTED ON EXHIBIT 4(D) ATTACHED HERETO AND INCORPORATED HEREIN BY REFERENCE (THE
"RADIATION ACCOUNTS RECEIVABLE"), OHAWB, THROUGH ITS AGENT, MEDICAL SPECIALTY
SUPPORT, WILL CONTINUE TO BILL AND COLLECT ALL RADIATION ACCOUNT RECEIVABLE ON
BEHALF OF RESPONSE, IN THE ORDINARY COURSE AND SHALL ENSURE THE PROMPT AND
ON-GOING PAYMENT OF AMOUNTS SO COLLECTED TO RESPECT ON A WEEKLY BASIS. AS
COMPENSATION THEREFOR, OHAWB SHALL BE ENTITLED TO 7% OF ALL AMOUNTS ACTUALLY
COLLECTED. I SHALL UTILIZE SUBSTANTIALLY THE SAME COLLECTION PRACTICES AS IT HAS
PROVIDED PRIOR TO CLOSING. FURTHER, RESPONSE SHALL BE ENTITLED TO REVIEW, COPY,
AND TRANSMIT INCOMING PAYMENTS, EXPLANATIONS OF BENEFITS AND OTHER
CORRESPONDENCE AND DOCUMENTS RELATING TO THE RADIATION ACCOUNTS RECEIVABLE, AS
WELL AS, TO "READ ONLY" ACCESS TO THE RELEVANT MEDICAL BILLING INFORMATION
SYSTEM FOR DATES OF SERVICE SUBSEQUENT TO THE CLOSING DATE. THE PARTIES AGREE TO
AMEND EXHIBIT 4(D), LISTING THE RADIATION ACCOUNTS RECEIVABLE TO MORE ACCURATELY
REFLECT THE SAME WITHIN TWENTY (20) DAYS AFTER CLOSING. OHAWB SHALL NOT MAKE
ADJUSTMENTS TO THE RADIATION ACCOUNTS RECEIVABLE OTHER THAN TO REFLECT
CONTRACTUAL ALLOWANCES AND POST PAYMENTS. OHAWB SHALL NOT WRITE OFF ANY OF SUCH
RADIATION ACCOUNTS RECEIVABLE WITHOUT THE PRIOR WRITTEN APPROVAL OF RESPONSE.
FURTHER, OHAWB AGREES TO EXERCISE REASONABLE COMMERCIAL CARE AND DILIGENCE IN
ITS COLLECTION EFFORTS AND SHALL NOT TAKE ACTION WHICH IS INCONSISTENT WITH
EITHER APPLICABLE LAW, RULE, OR REGULATION AFFECTING THE COLLECTION OF DEBTS
AND/OR PRIOR COLLECTION PRACTICES.]

        5. Premises and Equipment Leases. Subject to the terms and conditions
set forth in this Agreement, by assignment or other appropriate instrument of
transfer, Response shall assign to Oncology the premises lease for the Baptist
Medical Arts Building, East Tower, 8940 North Kendall Drive, Suite 302E,
business location (the "ASSIGNED LEASE") and Oncology shall assume and agree to
perform and to pay when due all remaining obligations on the Assigned Lease.
Copies of all of the premises leases for the business locations in which
Oncology operates (the "PREMISES LEASES") have been provided to Oncology and a
listing of same is attached as EXHIBIT 5(I) hereto. Copies of all of the leases
on equipment and other tangible personal property utilized by Oncology at any of
its

                                       4
<PAGE>

business locations (the "EQUIPMENT LEASES") have been provided to Oncology and a
listing of same is attached as composite EXHIBIT 5(II) hereto. The parties
acknowledge and agree that in the event the Assigned Lease cannot be transferred
or assigned by Response without the consent of or notice to a third party and in
respect of which any necessary consent or notice has not as of the Closing Date
been given or obtained, Response covenants and agrees (a) to use reasonable
means to obtain and to secure such consent and give such notice as may be
required to effect a valid transfer of such property, assets, or rights, and (b)
to make or complete such transfer or transfers as soon as reasonably possible.
Further, in the event Response is required to remain primarily obligated under
the Assigned Lease, notwithstanding the assignment and assumption, Oncology
shall indemnify Response from and hold it harmless against any and all costs,
expenses, claims, or liabilities to which Response is subject, which should
properly be attributable to Oncology as a result of the assignment and
assumption of leases. Response shall assign to Oncology its interests, if any,
in the Premises Leases and Equipment Leases and Oncology shall assume and agree
to perform and to pay when due all remaining obligations on the Premises Leases
and Equipment Leases. Notwithstanding the foregoing, all obligations under the
Premises Leases and the Equipment Leases shall be prorated as of the Closing
Date and, Response shall remain obligated for and shall indemnify Oncology from
and hold it harmless against, any amounts due through the Closing Date and
Oncology shall be obligated for and shall indemnify Response from and hold it
harmless against any amounts from and after the Closing Date.

        6. Purchase and Sale. Subject to the terms and conditions set forth in
this Agreement, Response agrees to sell, convey, transfer, assign and deliver to
Oncology, free and clear of all liens and encumbrances, and Oncology agrees to
purchase from Response for the cash purchase price set forth in SECTION 7 below,
certain of the assets of Response consisting of all or substantially all of the
assets used in the operation of Oncology's business, as described below:

           (a) All property, furniture, fixtures, and equipment currently
utilized by Oncology in its practice at any location, a list of which is
attached as EXHIBIT 6(A) hereto and incorporated herein by reference (the
"PERSONAL PROPERTY"). The purchase price allocated to the Personal Property is
intended to be the book value thereof as reflected on the books and records of
Response, as further described in accordance with SECTION 7 hereof;

           (b) All usable supply inventory, both on hand at the offices of
Oncology and in transit, as listed on EXHIBIT 6(B) hereto and incorporated
herein by reference (the "SUPPLY INVENTORY"). The parties agree to amend EXHIBIT
6(B) to more accurately reflect the actual amount of supply inventory within
twenty (20) days after the Closing Date. The purchase price allocated to the
Supply Inventory is intended to be the cost price thereof, as further described
in accordance with SECTION 7 hereof;

           (c) All of Response's rights in and to all of the unused portion of
expenses which have been prepaid in connection with the assets transferred
hereunder ("PREPAID EXPENSES") and in deposits and advances which have been paid
in connection therewith, including, but not limited to, the Premises Leases and
the Equipment Leases ("DEPOSITS AND ADVANCES") in the amount set forth in
SECTION 7 hereof. The Deposits and Advances and Prepaid Expenses are listed and
described on EXHIBIT 6(C) attached hereto and incorporated herein by reference.
The parties agree to amend

                                       5
<PAGE>

EXHIBIT 6(C) to more accurately reflect the actual amount of Deposits and
Advances within twenty (20) days after Closing;

           (d) All of the goodwill associated with Oncology's practice;

           (e) The parties agree that, upon the updating of EXHIBITS 6(B), 6(C),
AND 8, and in any case, no later than twenty (20) days after the Closing Date
appropriate adjusting payments, if any, will be made;

           (f) The parties acknowledge and agree that in the event any property,
assets or rights to be transferred or assigned to Oncology cannot be transferred
or assigned by Response without the consent of or notice to a third party and in
respect of which any necessary consent or notice has not as of the Closing Date
been given or obtained, Response covenants and agrees (a) to hold such property,
assets or rights for the use of Oncology; (b) to use reasonable means to obtain
and to secure such consent and give such notice as may be required to effect a
valid transfer of such property, assets, or rights; and (c) to make or complete
such transfer or transfers as soon as reasonably possible.

        7. Allocation of Purchase Price and Termination Fee. The purchase price
and Termination Fee shall be allocated, subject to adjustments, prorations,
credits and setoffs described herein, in the manner set forth below (the
"PURCHASE PRICE AND TERMINATION FEE ALLOCATION"):

<TABLE>
<S>                                                                          <C>
          Termination of Restrictive Covenants and Sale of Good Will       $  200,000
          Supply Inventory                                                 $   10,000
          Personal Property                                                $   45,000
          Deposits and Advances and Prepaid Expenses                       $   86,000
          Termination Fee (as described in paragraph 2(a)                  $3,498,000
          TOTAL CASH PURCHASE PRICE                                        $3,839,000
</TABLE>

        Response and Oncology each hereby covenant and agree that they will not
take a position that is in any manner inconsistent with this SECTION 7 on any
income tax returns, before any governmental agency charged with the collection
of any income tax or in any judicial, quasi-judicial and/or administrative
proceedings. The parties acknowledge that the Non-Medicare Accounts Receivable
are being assigned and an amount equal to the proceeds of the Medicare Accounts
Receivable are being paid in full satisfaction of the Receivables Line.

        8. Accounts Payable.

           (a) Response shall remain obligated for and agree to pay in full when
due, consistent with the prior business practices of Response, all trade
accounts payable and other liabilities arising from or created in connection
with Oncology's business prior to the Closing Date, including, but not limited
to, the accounts payable listed on EXHIBIT 8 attached hereto and incorporated
herein by reference (the "ACCOUNTS PAYABLE") except the liabilities existing
under the Equipment Leases, the Premises Leases, the Assigned Lease and any
other contracts which will be assumed or continued by Oncology on and after the
Closing Date. Response agrees that the

                                       6
<PAGE>

Accounts Payable (as herein defined to include obligations arising through the
Closing Date) are the sole obligation of Response (notwithstanding that invoices
therefor may list the purchaser as Oncology) and agrees to pay the Accounts
Payable in full when due and consistent with the prior business practices of
Response.

           (b) The parties agree to amend EXHIBIT 8 within twenty (20) days
after the Closing Date to accurately reflect actual Accounts Payable as of the
day before the Closing Date, consistent with the prior practices of Oncology and
Response. As described in SUBPARAGRAPH 6(E) above, an appropriate adjusting
payment shall be made by Response to Oncology or Oncology to Response, as
appropriate, within twenty (20) days after the Closing Date.

        9. Termination of Restrictive Covenants/Payment for Goodwill. In
consideration of the sum of Two Hundred Thousand Dollars ($200,000.00), which
Oncology shall pay to Response simultaneously with the Closing hereof, in
addition to the sale of goodwill described in SECTION 6(D), the restrictive
covenants of the physicians employed by Oncology (described in Article 7 of the
Service Agreement) are hereby terminated.

        10. Releases.

            (a) Except for its rights and Oncology's obligations arising from
this Agreement, Response does hereby remise, release, acquit, satisfy, and
forever discharge Oncology and Oncology's present and former shareholders,
officers, directors, employees, agents and attorneys and its and their heirs,
successors, and employees, and each of them (collectively "ONCOLOGY'S
REPRESENTATIVES"), of and from, any and all manner of actions, causes of action,
suits, debts, dues, sums of money, accounts, reckonings, bonds, bills,
specialties, covenants, contracts, controversies, agreements, promises,
variances, trespasses, damages, judgments, executions, claims and demands
whatsoever, in law or in equity or otherwise, whether known or unknown, matured
or unmatured, which Response ever had, now has, hereafter can, shall or may have
against Oncology and/or Oncology's Representatives arising from or relating to
acts or omissions which occurred prior to the Closing Date (specifically
including, but not limited to, the restrictive covenants referred to in SECTION
9 above) except those relating to medical malpractice claims and those relating
to fraudulent acts or omissions by Oncology and/or Oncology's Representatives.
Notwithstanding the foregoing, in the event that any claim(s) relating to
statements or submissions made to governmental or other payors is asserted
against Response or Response's Representatives (as defined below), or any of
them, by a person or entity which is not a party to this Agreement, Response or
Response's Representatives (as defined below), and each of them, hereby
specifically reserve and retain any and all rights, claims, and defenses which
they, or any of them, now have, have had, or would otherwise have against
Oncology or Oncology's Representatives, or any of them, arising out of the
act(s) or omission(s) which is the subject matter of each claim(s) against
Response or Response's Representatives (as defined below), or any of them.

            (b) Except for its rights and Response's obligations arising from
this Agreement, Oncology does hereby remise, release, acquit, satisfy, and
forever discharge Response and Response's present and former shareholders,
officers, directors, employees, agents and attorneys and its and their heirs,
successors, and assigns, and each of them, (collectively "RESPONSE'S
REPRESENTATIVES"), of and from, any and all manner of actions, causes of action,
suits, debts, dues,

                                       7
<PAGE>

sums of money, accounts, reckonings, bonds, bills, specialties, covenants,
contracts, controversies, agreements, promises, variances, trespasses, damages,
judgments, executions, claims and demands whatsoever, in law or in equity or
otherwise, whether known or unknown, matured or unmatured, which Oncology ever
had, now has, hereafter can, shall or may have against Response and/or
Response's Representatives, arising from or relating to facts or circumstances
which occurred prior to the Closing Date, except those relating to fraudulent
acts or omissions by Response and/or Response's Representatives. Notwithstanding
the foregoing, in the event that any claim(s) relating to statements or
submissions made to governmental or other payors is asserted against Oncology or
Oncology's Representatives, or any of them, by a person or entity which is not a
party to this Agreement, Oncology or Oncology's Representatives, hereby
specifically reserve and retain any and all rights, claims, and defenses, which
they, or any of them, now have, have had, or would otherwise have against
Response or Response's Representatives, or any of them, arising out of the
act(s) or omission(s) which is the subject matter of each claim(s) against
Oncology or Oncology's Representatives, or any of them.

            (c) The parties agree that their respective liability for any claim
relating to statements or submissions made to governmental or other payors shall
be allocated among the parties pro rata as follows with respect to the charge
giving rise to such claim(s): (i) for charges made after January 1, 1998, 88.5%
to OHAWB and 11.5% to Response. Notwithstanding the relative obligation
therefor, the parties agree that prior to any payment being made by either party
in regard to any such claim(s) relating to statements or submissions made to
governmental or other payors, both parties will use their best efforts to
resolve such claims in the most cost efficient manner.

        11. Employees. Effective as of the Closing Date, the employment of any
Executive Director (as such position is described in SECTION 5.6 of the Service
Agreement)and all other administrative personnel employed by Response at a
Clinic (as defined under SECTION 2.1 of the Service Agreement) shall be
terminated effective as of the Closing Date. All of such individuals shall be
hired by Oncology as employees simultaneous with such persons' termination of
employment by Response, effective as of the Closing Date. All expenses of
employment, including, but not limited to, salaries, benefits, taxes, insurance
and other costs, shall be prorated as of the Closing Date. Oncology agrees that,
for a period of two (2) years after Closing, neither it nor Oncology's
Representatives will actively solicit or attempt to influence any employee of
Response to terminate his or her relationship with Response nor will it employ
any such individual or former Response employee (within twelve (12) months of
the effective date of the individual's termination of his or her employment with
Response.)

        12. Impact Center Service Agreement and Pharmacy Services Agreement.
Effective as of the Closing Date, the parties shall execute and deliver a new
service agreement limited to the ancillary services of the Impact Center (as
defined in the Service Agreement), upon terms and conditions materially the same
as the current Service Agreement relating to the Impact Center and reflecting
the expansion of Impact Center services to the treatment of certain chronic
diseases. Effective as of the Closing Date and as a condition precedent to
Response's Obligation to close, the parties shall execute and deliver an
Agreement for Pharmacy Services in the form attached hereto as EXHIBIT 12.

                                       8
<PAGE>

        13. Representations and Warranties of Oncology. Oncology represents,
warrants, covenants and agrees with Response that:

            (a) Organization. Oncology is a professional association duly
organized, validly existing and in good standing under the laws of the State of
Florida. Oncology has the full power and authority to own its property, to carry
on its business as presently being conducted, to enter into this Agreement, and
to consummate the transactions contemplated hereby.

            (b) Authority. Oncology has taken all necessary action to authorize
the execution, delivery, and performance of this Agreement as well as the
consummation of the transactions contemplated hereby. The execution and delivery
of this Agreement do not, and the consummation of the transactions contemplated
hereby will not violate any provisions of the charter or the bylaws of Oncology
or any indenture, mortgage, deed of trust, lien, lease agreement, arrangement,
contract, instrument license, order, judgment or decree, or result in the
acceleration of any obligation thereunder, to which Oncology is a party or by
which it is bound.

            (c) Litigation. No action or proceeding by or before any court or
other Governmental Authority has been instituted or is, to the best of
Oncology's knowledge, threatened with respect to the transactions contemplated
by this Agreement.

            (d) Full Disclosure. When considered in the context of all
information contained herein, no representation or warranty made by Oncology in
this Agreement contains or will contain any untrue statement of a material fact.
All representatives and warranties contained in this Agreement are true and
correct as of the date of their Agreement and shall remain true and correct
throughout the term of this Agreement.

            (e) Fair Consideration. Oncology has reviewed each and every term
and provision of this Termination Agreement with counsel of its choosing and has
accepted same as being fair and reasonable. Oncology acknowledges that the
consideration tendered to Response is fair and reasonable and constitutes a
reasonably equivalent value for the consideration paid to it by Response.
Oncology acknowledges that the tender of the consideration to Response is not
undertaken in fraud of or to hinder or delay any of its creditors and will not
render it insolvent.

        14. Representations and Warranties of Response. Response represents,
warrants, covenants and agrees with Oncology that:

            (a) Organization. Response is a corporation duly organized, validly
existing and in good standing under the laws of the State of Tennessee. Response
has the full power to own its property, to carry on its business as presently
conducted, to enter into this Agreement, and to consummate the transactions
contemplated hereby.

            (b) Authority. Response has taken all necessary action to authorize
the execution, delivery, and performance of this Agreement as well as the
consummation contemplated hereby. The execution and delivery of this Agreement
do not, and the consummation of the transactions contemplated hereby will not,
violate any provisions of the charter or the bylaws of Response or any
indenture, mortgage, deed of trust, lien, lease agreement, arrangement,
contract, instrument license,

                                       9
<PAGE>

order, judgment or decree, or result in the acceleration of any obligation
thereunder, to which Response is a party or by which it is bound.

            (c) Litigation. No action or proceeding by or before any court or
other Governmental Authority has been instituted or is, to the best of
Response's knowledge, threatened with respect to the transactions contemplated
by this Agreement.

            (d) Full Disclosure. When considered in the context of all
information contained herein, no representation or warranty made by Response in
this Agreement contains or will contain any untrue statement of a material fact.
All representatives and warranties contained in this Agreement are true and
correct as of the date of this Agreement and shall remain true and correct
throughout the term of this Agreement.

            (e) Fair Consideration. Response has reviewed each and every term
and provision of this Termination Agreement with counsel of its choosing and has
accepted same as being fair and reasonable. Response acknowledges that the
consideration tendered to Oncology is fair and reasonable and constitutes a
reasonably equivalent value for the consideration paid to it by Oncology.
Response acknowledges that the tender of the consideration to Oncology is not
undertaken in fraud of or to hinder or delay any of its creditors and will not
render it insolvent.

            (f) No Liens or Encumbrances. Upon delivery to Oncology and
appropriate filing of the documents described in SECTION 4(A) and (B) above, the
assets to be transferred hereunder shall be delivered free and clear of any
liens or encumbrances except those which have arisen, directly or indirectly, as
a result of the following obligations being assumed by Oncology: [THE ASSIGNED
LEASE, THE PREMISES LEASES AND THE EQUIPMENT LEASES].

        15. Closing. The Closing of the transactions contemplated hereby,
including, but not limited to, the transfer of assets and leases by Response to
Oncology (the "CLOSING"), shall take place simultaneously with the execution and
delivery of this Agreement (the "CLOSING DATE") at the offices of OHAWB's
counsel, Abrams Anton, P.A., 2021 Tyler Street, Hollywood, Florida 33022, or on
such other date and at such other place as the parties may agree to in writing.

            (a) At the Closing, Response shall execute and deliver, or cause to
be delivered, to Oncology the following instruments and documents, against
execution and delivery of the items specified in SECTION 15(B):

                (i)     The original note and/or other instruments establishing
                        and/or securing the Receivables Line marked satisfied in
                        full.

                (ii)    Assignment of Response's interests in the Assigned Lease
                        as described in SECTION 5 above.

                (iii)   Assignment(s) of Response's interest, if any, in the
                        Premises Leases and the Equipment Leases.

                (iv)    Consent(s) to the assignment and assumption of the
                        Assigned Lease.

                                       10
<PAGE>

                (v)     A bill of sale and/or assignment instrument(s) conveying
                        title to any other assets to be transferred hereunder
                        not already conveyed by the deliverables described in
                        SUBSECTIONS 15(A)(II) AND (III), free and clear of liens
                        and encumbrances, except those described in SECTION
                        14(F).

                (vi)    A consent to the termination of restrictive covenants as
                        described in SECTION 9 above.

                (vii)   An assignment of goodwill, as described in SECTION 6(D)
                        above.

                (viii)  Response's corporate resolutions of directors
                        authorizing the transaction.

            (b) At the Closing, Oncology shall execute and deliver, or cause to
be delivered, to Response the following instruments and documents against
execution and delivery of the items specified in SECTION 15(A):

                (i)     A cashier's or trust account check or wire transfer in
                        the amount of the Termination Fee, subject to
                        adjustments, prorations, credits, and setoffs described
                        herein.

                (ii)    A cashier's or trust account check or wire transfer in
                        the amount of the Purchase Price for the Personal
                        Property, Supply Inventory, and Prepaid Expenses and
                        Deposits and Advances as set forth in SECTION 7 hereof,
                        subject to adjustments, prorations, credits, and setoffs
                        described herein.

                (iii)   A cashier's or trust account check or wire transfer in
                        the amount of Two Hundred Thousand Dollars ($200,000.00)
                        pursuant to SECTION 9 hereof.

                (iv)    The original Response Note marked satisfied in full.

                (v)     Evidence of termination of the Response Stock Options as
                        described in SECTION 3 hereof.

                (vi)    An assignment of Oncology's interest, if any, in its
                        Non-Medicare Accounts Receivable to Response, subject to
                        the terms and conditions hereof.

                (vii)   A Security Agreement executed by Oncology giving
                        Response a first priority Security Interest in and to
                        the Medicare Accounts Receivable as described in SECTION
                        4 above.

                                       11
<PAGE>

                (viii)  A general assumption instrument assuming the Assigned
                        Lease, the accounts payable arising from and after the
                        Closing Date, and any other obligations to be assumed
                        hereunder.

                (ix)    Consents, if any, as the same shall be required to the
                        assignment and assumption of leases.

                (x)     An Agreement for Pharmacy Services effective as of the
                        Closing Date by and between Response and Oncology, in
                        the form set forth at EXHIBIT 12 and executed by
                        Oncology.

                (xi)    Oncology's corporate resolutions of shareholders and
                        directors authorizing the transaction.

            (c) Each of the parties, at any time before or after the Closing
Date, will execute, acknowledge and deliver any further documents, instruments,
assignments, and other instruments of transfer, reasonably requested by the
other party, and will take any other action consistent with the terms of this
Agreement that may reasonably be requested by the other party for the purpose of
assigning, transferring, granting, conveying, and confirming to the other party,
or reducing to possession, any or all property to be conveyed and transferred by
this Agreement.

        16. Indemnification.

            (a) Each party hereby indemnifies the other from and holds it
harmless against any and all damages, claims, losses, expenses, costs,
obligations and liabilities (including, without limitation, reasonable
attorneys' fees) suffered by the other party resulting from or arising in
connection with any material false or incorrect representations or warranties
made by the indemnifying party hereunder, or the breach by the indemnifying
party of any of its covenants or agreements hereunder.

            (b) Oncology hereby indemnifies Response from and holds it harmless
against any and all damages incurred or suffered by Response that result from,
relate to or arise out of any and all actions, suits, claims, legal,
administrative, arbitration, governmental or other proceedings or other
investigations against or involving Response that relate to Oncology or the
business to which this transaction relates in which the principal event giving
rise thereto (i) occurred after the Closing Date or which results from or arises
out of any action or inaction of Oncology or any employee, agent, or
representative of Oncology after the Closing Date; or (ii) is an act or omission
by Oncology that occurred prior to, on, or after the Closing Date and arose from
or is related to the provision of or failure to provide patient care or related
services; or (iii) relates to any statement or submission made to governmental
or other payors; provided, that as to matters falling within clause (iii), the
indemnification obligation shall be reduced by Response's allocable obligation
for such claim, as described in SECTION 10(C).

            (c) Response hereby indemnifies Oncology from and holds it harmless
against any and all damages incurred or suffered by Oncology that result from,
relate to, or arise out of any and all actions, suits, claims, legal,
administrative, arbitration, governmental or other proceedings, or

                                       12
<PAGE>

other investigations against or involving Oncology that relate to Response or
the business to which this transaction relates in which the principal event
giving rise thereto (i) occurred prior to the Closing Date and does not involve
the provision of or failure to provide patient care or related issues of
record-keeping related to such services or which results from or arises out of
any action or inaction of Response or any employee, agent, or representative of
Response prior to the Closing Date; or (ii) occurred prior to, on, or after the
Closing Date and involves a claim by any creditor of Response, including, but
not limited to, AmSouth; provided, that with respect to any such matter that may
involve a statement or submission made to governmental or other payors, the
indemnification obligation shall be reduced by OHAWB's allocable share, as
described in Section 10(c).

            (d) If any person or entity not a party hereto (the "NON-PARTY
CLAIMANT") notifies any party to this Agreement (the "INDEMNIFIED PARTY") with
respect to any matter (a "NON-PARTY CLAIM") which may give rise to a claim for
indemnification against any other party to this Agreement (the "INDEMNIFYING
PARTY"), then the Indemnified Party shall promptly (and in any event within
fifteen (15) business days after receiving notice of the Non-Party Claim) notify
each Indemnifying Party thereof in writing. Such written notice shall specify
the nature and the amount of the claim(s) made or anticipated to be made and the
identity of the Non-Party Claimant and shall be accompanied by copies of any
documents provided to the Indemnified Party by the Non-Party Claimant in
connection with the making of such Non-Party Claim.

        17. Brokers. Each of the parties represents and warrants that it has
dealt with no broker or finder in connection with any of the transactions
contemplated by this Agreement and, insofar as it knows, no broker is entitled
to a commission or finder's fee in connection with any of these transactions.
Response and Oncology each agree to indemnify and hold harmless one another
against any loss, liability, damage, cost, claim, or expense incurred by reason
of any brokerage, commission, or finder's fee alleged to be payable because of
any act, omission, or statement of the indemnifying party.

        18. Costs. Except as may otherwise be provided in this Agreement, each
of the parties shall pay all costs and expenses incurred or to be incurred by it
in negotiating and preparing this Agreement and in closing and carrying out the
transactions contemplated by this Agreement.

        19. Prorations. Rent, utilities, telephone charges, personal property
taxes, employee wages, salaries, and benefits, and all other comparable expenses
capable of proration shall be prorated as of the Closing Date.

        20. Additional Post-Closing Covenants.

            (a) Notwithstanding the termination of the Service Agreement,
Response shall cause to be paid to Oncology or the Physicians employed by
Oncology, as appropriate, the retainage amount applicable to January, 2001, in a
manner consistent with prior practice.

            (b) For a period of four years following the Closing Date, Response
shall continue to maintain Leonard Kalman, M.D. as a named insured on Response's
director's and officer's insurance for dates up to and including the Closing
Date.

                                       13
<PAGE>

        21. Miscellaneous Provisions.

            (a) This Agreement represents the entire understanding and agreement
between the parties with respect to the subject matter hereof, and supersedes
all other negotiations, understandings and representations (if any) made by and
between such parties.

            (b) The provisions of this Agreement may be amended, supplemented,
waived, or changed only by a writing signed by the party against whom
enforcement of any such amendment, supplement, waiver, or modification is sought
and making specific reference to this Agreement.

            (c) Neither party may assign its rights and/or delegate its
obligations hereunder without the prior written consent of the other party,
which consent shall not be unreasonably withheld.

            (d) All of the terms and provisions of this Agreement, whether so
expressed or not, shall be binding upon, inure to the benefit of, and be
enforceable by the parties and their respective legal representatives,
successors and permitted assigns.

            (e) All notices, requests, consents and other communications
required or permitted under this Agreement shall be in writing (including
facsimile and telegraphic communication) and shall be (as elected by the person
giving such notice) hand delivered by messenger or courier service,
telecommunicated (to be followed by hard copy by overnight delivery), or mailed
(airmail if international) by registered or certified mail (postage prepaid),
return receipt requested, addressed to such address as any party may designate
by notice complying with the terms of this Section. Each such notice shall be
deemed delivered (a) on the date delivered if by personal delivery, and (b) on
the date upon which the return receipt is signed or delivery is refused or the
notice is designated by the postal authorities as not deliverable, as the case
may be, if mailed.

            (f) If any part of this Agreement or any other Agreement entered
into pursuant hereto is contrary to, prohibited by or deemed invalid under
applicable law or regulation, such provision shall be inapplicable and deemed
omitted to the extent so contrary, prohibited, or invalid, but the remainder
hereof shall not be invalidated thereby and shall be given full force and effect
so far as possible.

            (g) In this Agreement, the use of any gender shall be deemed to
include all genders, and the use of the singular shall include the plural,
wherever it appears appropriate from the context.

            (h) The failure or delay of any party at any time to require
performance by another party of any provision of this Agreement, even if known,
shall not affect the rights of such party to require performance of that
provision or to exercise any right, power, or remedy hereunder, and any waiver
by any party of any breach of any provision of this Agreement shall not be
construed as a waiver of the provision itself, or a waiver of any right, power,
or remedy under this Agreement. No notice to or demand on any party in any case
shall, of itself, entitle such party to any other or further notice or demand in
similar or other circumstances.

                                       14
<PAGE>

            (i) Nothing in this Agreement, whether express or implied, is
intended to confer any rights or remedies under or by reason of this Agreement
on any person other than the parties hereto and their respective legal
representatives, successors and permitted assigns, nor is anything in this
Agreement intended to relieve or discharge the obligation or liability of any
third persons to any party to this Agreement, nor shall any provision give any
third persons any right of subrogation or action over or against any party to
this Agreement.

            (j) No remedy herein conferred upon any party is intended to be
exclusive of any other remedy, and each and every such remedy shall be
cumulative and shall be in addition to every other remedy given hereunder or now
or hereafter existing at law or in equity or by statute or otherwise. No single
or partial exercise by any party of any right, power, or remedy hereunder shall
preclude any other or further exercise thereof.

            (k) This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

            (l) This Agreement and all transactions contemplated by this
Agreement shall be governed by, and construed and enforced in or accordance
with, the internal laws of the State of Florida without regard to principles of
conflicts or choice of laws.

            (m) Any suit, action, or other legal proceeding arising out of or
relating to this Agreement shall be brought in a court of the State of Florida,
Dade County, or in the United States District Court for the Southern District of
Florida, having subject matter jurisdiction thereof, and both parties agree to
submit to the jurisdiction of such forum.

            (n) Each covenant set forth in SECTIONS 2(B), 4, 5, 6, 7, 8(B), 10,
11, 12, 15(C), 16, 19, 19(A), 20(M), 20(N), AND 20(O) shall survive the Closing
and delivery of the documents and other deliverables contemplated herein.

            (o) Without the prior written consent of the other party, neither
party will disclose any term or condition of this Agreement to any person or
entity except that such disclosure may be made (i) to any lender to or other
person in a business relationship with any of the parties to whom such
disclosure is necessary in order to satisfy any of the conditions to the
consummation of this Agreement; (ii) to the extent appropriate, by each party,
to employees and legal counsel of that party; and (iii) to the extent the party
making such disclosure believes in good faith that such disclosure is required
by law (in which case such party will consult with the other party prior to
making such disclosure). Oncology hereby consents to the public announcement
Response will make on or after the Closing Date announcing the consummation of
the Agreement and the transactions contemplated thereby. No press release or
other public announcement related to this Agreement or the transactions
contemplated hereby will be issued by any party hereto without the prior
approval of the other party, except that any party may make such public
disclosure which it believes in good faith to be required by law (in which case
such party will consult with the other party prior to making such disclosure).

            (p) If any legal action or other proceeding is brought for the
enforcement of this Agreement, or because of an alleged dispute, breach,
default, or misrepresentation in connection with any provisions of this
Agreement, the successful or prevailing party or parties shall be entitled to

                                       15
<PAGE>

recover reasonable attorneys' fees and expenses, court costs and all expenses
even if not taxable as court costs (including, but not limited to, all
attorneys' fees and expenses incident to any appeals), incurred in that action
or proceeding, in addition to any other relief to which such party or parties
may be entitled.

            (q) The parties hereby agree from time to time to execute and
deliver such further and other transfers, assignments and documents and do all
matters and things which may be convenient or necessary to more effectively and
completely carry out the intentions of this Agreement.

               [REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY.]

                                       16
<PAGE>

         IN WITNESS WHEREOF, the parties have duly executed this Agreement as of
the date first above written.

OHAWB HEMATOLOGY GROUP OF SOUTH               RESPONSE ONCOLOGY, INC.,
FLORIDA, P.A.,                                a Tennessee corporation
a Florida professional service corporation

By:                                           By:
    --------------------------------------        ------------------------------
President:                                    President:
          --------------------------------              ------------------------

                                       17<PAGE>
                                                                  EXHIBIT 10(ad)

                       ASSET PURCHASE/SETTLEMENT AGREEMENT

                                  BY AND AMONG

                 HEM-ONC ASSOCIATES OF THE TREASURE COAST, P.A.
                       A FLORIDA PROFESSIONAL ASSOCIATION

                                 ALAN S. COLLIN
                              NICHOLAS O. IANNOTTI
                                 PAUL M. SWANSON
                               MICHAEL S. WERTHEIM

                                       AND

                             RESPONSE ONCOLOGY, INC.
                             A TENNESSEE CORPORATION

                                       AND

                              ANTHONY M. LAMACCHIA

                                      DATED

                                 MARCH 15, 2002

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<S>                                                                                       <C>
RECITALS...................................................................................1
1.    Purchased Assets.....................................................................2
   (a)      Tangible Personal Property.....................................................2
   (b)      Contracts......................................................................2
   (c)      Prepaids.......................................................................3
   (d)      Records........................................................................3
   (e)      Practice Name..................................................................3
2.    Termination of Service Agreement/Settlement of all Claims............................3
   (a)      Termination of Service Agreement...............................................3
   (b)      Modification of Service Fee....................................................3
3.    Purchased Assets - Free and Clear of Liens/Release of Liens on Hem-Onc's Assets......4
4.    Purchase Price.......................................................................5
   (a)      Purchased Assets Consideration.................................................5
   (b)      Consideration for Termination of Agreement and Settlement of Claims............5
5.    Payments of the Purchase Price.......................................................6
   (a)      Payments at Closing............................................................6
   (b)      Response Payments..............................................................6
   (c)      Escrow.........................................................................6
   (d)      Prorations.....................................................................7
   (e)      Payment of Post-Petition Accrued Clinic Expenses...............................7
   (f)      Closing Date and Place/Closing Deliveries......................................8
6.    Payment Reconciliation...............................................................8
   (a)      Final Reconciliation...........................................................8
   (b)      Reconciliation Payments/Payment Credits........................................9
   (c)      Dispute Resolution............................................................10
   (d)      Purpose of Reconciliation.....................................................10
7.    Payment of Certain Expenses at or after Closing.....................................11
8.    No Assumption of Liabilities........................................................12
9.    Mutual Releases.....................................................................12
   (a)      Response's/LaMacchia's Releases...............................................12
   (b)      Hem-Onc's/Stockholders' Releases..............................................12
   (c)      Dismissal of Suits............................................................12
10.      Certain Covenants of the Parties/Court Approval..................................13
   (a)      Termination of Employment.....................................................13
   (b)      Bankruptcy Court Approval.....................................................13
11.      Management of Medical Practice...................................................14
   (a)      Response's Covenants..........................................................15
   (b)      Hem-Onc's/Stockholders' Covenants.............................................16
12.      Conditions of Closing............................................................16
   (a)      Compliance with Covenants of Parties..........................................17
   (b)      Approval of Agreement.........................................................17
   (c)      Representations and Warranties of the Parties.................................17
   (d)      New Leases for Certain Purchased Assets.......................................17
13.      No Bids..........................................................................17
</TABLE>

                                       i
<PAGE>
<TABLE>
<S>                                                                                       <C>
14.      Access to Records................................................................18
   (a)      Hem-Onc Access................................................................18
   (b)      Response Access...............................................................18
15.      Payment of Costs by Parties......................................................18
16.      Public Announcement/Confidentiality..............................................18
17.      Governing Law....................................................................18
18.      Banks' Approval..................................................................19
19.      Miscellaneous....................................................................19
   (a)      Survival......................................................................19
   (b)      Further Actions...............................................................19
   (c)      Amendments....................................................................19
   (d)      Notices.......................................................................20
   (e)      Binding/Assignment............................................................21
   (f)      Severability..................................................................21
   (g)      No Third Party Beneficiaries..................................................21
   (h)      No Strict Construction........................................................22
   (i)      Captions......................................................................22
   (j)      Complete Agreement............................................................22
   (k)      Counterparts..................................................................22
   (l)      Tax Allocation................................................................22
20.      Definitions......................................................................22
</TABLE>

                                    SCHEDULES
<TABLE>
<S>                  <C>
Schedule 1           Leases, contracts and Agreements of Response as of December 31, 2001
                     with respect to Hem-Onc

Schedule 2           Balance Sheet of Response as of December 31 2001

Schedule 5(f)        Closing/Closing Deliveries

Schedule 12(c)       Representations and Warranties
</TABLE>

                                       ii
<PAGE>

                       ASSET PURCHASE/SETTLEMENT AGREEMENT

        THIS ASSET PURCHASE/SETTLEMENT AGREEMENT (the "Agreement") is made as of
this 15th day of March, 2002, by and among HEM-ONC ASSOCIATES OF THE TREASURE
COAST, P.A., a Florida professional association ("Hem-Onc"), ALAN S. COLLIN
("Collin"), NICHOLAS O. IANNOTTI ("Iannotti"), PAUL M. SWANSON ("Swanson") and
MICHAEL S. WERTHEIM ("Wertheim") (Collin, Iannotti, Swanson and Wertheim are
sometimes referred to herein, individually, as a "Stockholder" and,
collectively, as the "Stockholders"), and RESPONSE ONCOLOGY, INC., a Tennessee
corporation ("Response") and ANTHONY M. LAMACCHIA ("LaMacchia").

                                    RECITALS

        WHEREAS, Response furnishes Hem-Onc with certain facilities, equipment,
supplies, support personnel and management, practice development and financial
advisory services pursuant to that certain Service Agreement, dated as of
October 1, 1996 (the "Service Agreement") by and between Response, a former
wholly-owned subsidiary of Response, Hem-Onc and the Stockholders; and

        WHEREAS, the Stockholders are the sole shareholders of Hem-Onc and
LaMacchia is the President and Chief Executive Officer of Response, and the
Stockholders and LaMacchia are members of that certain Oversight Committee
created under the Service Agreement to oversee the operation of Hem-Onc's
medical practice; and

        WHEREAS, Response and certain of its wholly-owned affiliates are debtors
in possession under cases (the "Bankruptcy Case") filed under Chapter 11 of
Title 11 of the United States Code (the "Bankruptcy Code") on March 29, 2001, in
the United States Bankruptcy Court for the Western District of Tennessee (the
"Bankruptcy Court"), and jointly administered under Case Number 01-24607 DSK;
and

        WHEREAS, a variety of material disputes have arisen between Hem-Onc and
the Stockholders, on one hand, and Response and LaMacchia, on the other hand,
some or most of which are the subject of an adversary proceeding, number
01-0502-DSK (the "Adversary Proceeding") or are included within various
contested matters pending in the Bankruptcy Case, including Hem-Onc's proof of
claims submitted in connection therewith; and

        WHEREAS, the parties desire to settle all disputes between the parties
and in connection therewith, terminate the Service Agreement and cause Response
to sell to Hem-Onc certain of Response's tangible personal property, leasehold
improvements, leases, agreements and contracts and certain of Response's books,
records and rights, which relate to Hem-Onc, in accordance with the terms and
conditions set forth herein.

                                       1
<PAGE>

        NOW, THEREFORE, in consideration of the mutual premises and covenants
and agreements of the parties hereto as set forth herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

     1. Purchased Assets. On the terms of and subject to the conditions of
this Agreement, on the Closing Date (as defined herein), Hem-Onc shall purchase
from Response, and Response shall sell, convey, assign, transfer and deliver to
Hem-Onc, all or substantially all tangible personal property and leasehold
improvements of Response which as of the Closing Date, pursuant to the Service
Agreement, are used exclusively by, or made available for the exclusive use of,
Hem-Onc in connection with its medical practice, together with certain books,
records, rights to certain prepayments and deposits, and leases, agreements and
contracts of Response which are used or useful in connection with the operation
of Hem-Onc's medical practice, as more particularly described as follows:

        (a) Tangible Personal Property. All tangible personal and real
property--furniture, fixtures, equipment, and leasehold improvements and real
property (the "Acquired Assets")--owned or leased by Response as of the Closing
Date (as defined below), including inventory and supplies and Response's
interests in leased real property, which, pursuant to the Service Agreement, are
used or held for use exclusively in the operation of Hem-Onc's medical practice
and which were acquired by Response to satisfy certain of its obligations under
the Service Agreement.

        (b) Contracts.

                (i) Those leases, contracts and agreements to which Response is
        a party and which are described on Schedule 1 attached hereto (but, only
        to the extent and only with respect to the provisions thereof which
        relate to assets or property used or held for use exclusively by
        Hem-Onc), together with such additional leases, contracts or agreements
        of Response expressly agreed to be assumed by Hem-Onc (collectively, all
        such leases, contracts and agreements are referred to as the "Assigned
        Contracts"), including maintenance agreements for the Acquired Assets,
        software license agreements for software used exclusively in connection
        with Hem-Onc's medical practice, which are in existence as of Closing
        and which were entered into by Response solely to satisfy certain of its
        obligations under the Service Agreement, together with all rights of
        Response under the Assigned Contracts, including rights to licensed
        software. All Assigned Contracts shall be current as of Closing.

                (ii) With regard to the real property leases (individually, a
        "Real Property Lease" and, collectively, the "Real Property Leases")
        included within the Assigned Contracts, Response, Hem-Onc and the
        Stockholders aver that, to their knowledge, no claims or cure
        obligations exist with respect thereto. Notwithstanding anything herein
        to the contrary, Hem-Onc and the Stockholders agree to use their
        reasonable efforts to obtain at or before Closing representations or
        agreements, as the case may be, from each of the "landlords" under each
        Real Property Lease to the effect that: (1) no claims or cure
        obligations exist under each said Real Property Lease; or (2) if

                                       2
<PAGE>

        any claim or cure obligation exists with respect to any such Real
        Property Lease, such claims or cures shall be waived in full by each
        such landlord. If any such claims or cure obligations do exist, and the
        applicable landlord does not waive the same, then Hem-Onc agrees to pay
        such claim or cure obligation, but only to the extent known as of
        Closing and only to the extent that Hem-Onc receives a credit towards
        payment of the Purchase Price (as defined below) as a result of such
        agreement to pay.

        (c) Prepaids. All rights of Response, as of Closing, to all prepayments
of Clinic Expenses (as defined in the Service Agreement), prepaid service
contracts (to the extent such contracts are included in the Assigned Contracts)
and all deposits paid by Response under the Assigned Contracts or with respect
to goods or services provided to or on behalf of Hem-Onc, which are described
(or are of the type described) on Response's balance sheet (the "Balance Sheet")
for its Hem-Onc operations, dated December 31, 2001, a copy of which is attached
hereto as Schedule 2 (the "Assigned Prepayments").

        (d) Records. All lists and records of Response pertaining to suppliers,
vendors, personnel and patients doing business with, providing services to or
receiving medical services or goods from Hem-Onc, together with all other books,
ledgers, files, documents, correspondence, business analysis and records of
Response of any kind and nature which relate exclusively to Hem-Onc or Hem-Onc's
medical practice, to the extent the same have not already been provided to
Hem-Onc through discovery in the Adversary Proceeding (the "Assigned Records").

        (e) Practice Name. All rights of Response in and to the name "Hematology
Oncology Associates of the Treasure Coast", and all variations thereof (the
"Assigned Name").

        The Assigned Assets, Assigned Contracts, Assigned Prepayments, Assigned
Records and Assigned Name are, collectively, referred to herein as the
"Purchased Assets".

     2. Termination of Service Agreement/Settlement of all Claims.

        (a) Termination of Service Agreement. For the consideration recited
herein, in addition to purchasing the Purchased Assets, at Closing, the parties
agree that, at and as of Closing, the Service Agreement shall terminate, and in
connection therewith, effective as of Closing, all Claims (as defined below)
between the parties, including, but not limited to, those raised in the
Bankruptcy Case and the Adversary Proceeding, shall be waived and released. In
connection with the termination of the Service Agreement, the parties expressly
acknowledge and agree that all obligations of the parties thereunder, including
the non-competition and non-solicitation covenants of Hem-Onc and the
Stockholders, and any obligations of Hem-Onc and the Stockholders to Response
with respect to the terms of the Stockholders' Employment Agreements with
Hem-Onc, as otherwise set forth therein, shall terminate, in full, and shall be
of no further legal force or effect.

        (b) Modification of Service Fee. In consideration of Hem-Onc's closing
on the purchase of the Purchased Assets and its and the Stockholders' release of
all Claims which Hem-Onc or the Stockholders have or may have had against
Response, as otherwise provided in

                                       3
<PAGE>

Section 9(b) below, for all periods beginning on and after January 1, 2002 and
ending on or before Closing (the "Reconciliation Period"), Response shall not be
entitled to the Service Fee, as otherwise calculated for such periods in
accordance with Schedule A to the Service Agreement, but instead, in lieu
thereof, Hem-Onc shall only be obligated to pay or reimburse Response (without
interest) as follows:

                (i) reimburse Response for all post-petition Clinic Expenses (as
        defined in the Service Agreement) which are incurred at any time on or
        after January 1, 2002, and which are actually paid by Response (from its
        separate funds) during the Reconciliation Period or with respect to
        which Response agrees to pay after Closing, to the extent it escrows
        money to pay the same at Closing as and to the extent set forth in
        Section 7 below; plus

                (ii) reimburse Response for all Physician Expenses (as defined
        in the Service Agreement) actually paid by Response (from its separate
        funds) during the Reconciliation Period (regardless of when such
        expenses are accrued); plus

                (iii) reimburse Response for all capital expenditures ("Capital
        Expenditures") actually paid by Response (from its separate funds)
        solely for the benefit of Hem-Onc during the Reconciliation Period, but
        only to the extent that such Capital Expenditures result in the
        acquisition of a new asset (not owned as of December 31, 2001), to be
        included in the Purchased Assets, and which were authorized or requested
        by Hem-Onc, in writing, during the Reconciliation Period; and

                (iv) pay Response a monthly fixed performance fee (the "Monthly
        Fee") of $199,735 per month (prorated for partial months) for each month
        (or partial month) during the Reconciliation Period; provided that, if
        Closing has not occurred on or before March 31, 2002 through no fault of
        Hem-Onc or the Stockholders, then no Monthly Fee (or any other fee in
        lieu thereof) shall be paid Response for services rendered under the
        Service Agreement with respect to the period after March 31, 2002,
        through Closing.

        For this purpose, Response shall be treated as paying a Clinic Expense,
Physician Expense or Capital Expenditure, if paid in accordance with the terms
of the Service Agreement and Response's historical payment practices, as
modified in accordance with Section 11 below, and such expenses or expenditures
are paid from any account or source, other than an account owned by Hem-Onc
[including the Provider Receipts Account and the Provider Operating Account (as
defined in Section 5.11 of the Service Agreement)]. Expenses will be deemed paid
as provided in Section 6(d) below.

     3. Purchased Assets - Free and Clear of Liens/Release of Liens on Hem-Onc's
Assets. The Purchased Assets will be purchased and sold at Closing (as defined
herein), free and clear of all liens, claims and encumbrances. In addition, at
or before Closing, Response shall release or shall have obtained an order of the
Bankruptcy Court releasing, effective as of Closing, any and all liens, claims
and encumbrances on any assets of Hem-Onc or the Stockholders, including
Hem-Onc's Accounts Receivables (as defined in the Service Agreement)

                                       4
<PAGE>

and proceeds paid Hem-Onc with respect thereto, which either secure Hem-Onc's
obligations to Response under the Service Agreement or which secure any
obligations of Response, including indebtedness of Response to the Banks (as
defined below) or to any other creditor of Response. In furtherance thereof, on
March 1, 2002, Response filed a motion seeking the approval of this Agreement by
the Bankruptcy Court, including the Bankruptcy Court's approval of this
Agreement under Rule 9019 of the Federal Rules of Bankruptcy Procedure (the
"Bankruptcy Rules"), and Sections 105, 363 and 365 of the Bankruptcy Code.

     4. Purchase Price. The "Purchase Price" (as defined herein) shall equal
$3,093,725. The Purchase Price represents the sum of: (x) the purchase price for
the Purchased Assets, as set forth in Section 4(a) below; and (y) the
consideration payable by Hem-Onc to Response: (1) in connection with the
termination of the Service Agreement and the settlement of all Claims [other
than the Avoidance Claim (as defined below)]; and (2) in connection with the
settlement of the Avoidance Claim, both as set forth in Section 4(b) below:

        (a) Purchased Assets Consideration. The purchase price for the Purchased
Assets shall equal $810,270, representing the book value of such assets as of
December 31, 2001, as determined in accordance with generally accepted
accounting principles ("GAAP"), and consistent with Response's historical
accounting practices, consistently applied, as set forth in the Balance Sheet.

        (b) Consideration for Termination of Agreement and Settlement of Claims.

                (i) The aggregate amount payable by Hem-Onc and the Stockholders
        for the termination of the Service Agreement and the settlement of all
        Claims (including the Avoidance Claim), as otherwise required by this
        Agreement, shall equal $2,283,455.00. This sum (hereinafter the
        "Settlement Amounts") represents the outstanding balance (principal
        only) of advances paid by Response to or for the benefit of Hem-Onc, and
        the aggregate accrued, but unpaid, Service Fee (calculated in accordance
        with Schedule A to the Service Agreement), as of December 31, 2001, plus
        the settlement of the Avoidance Claim.

                (ii) As part of the consideration for the termination of the
        Service Agreement and the settlement of all Claims (that is, as part of
        the $2,283,455.00 Settlement Amounts), Hem-Onc agrees to pay Response
        $476,605.50 in full satisfaction of Response's claim for the same amount
        based on Response's contention that Hem-Onc transferred that amount to
        itself after the filing of Response's Bankruptcy Case on March 29, 2001
        (the "Avoidance Claim"). For purposes of the settlement effected by this
        Agreement, the parties agree that the Avoidance Claim is deemed
        recoverable by Response pursuant to Chapter 5 of the Bankruptcy Code,
        and that, pursuant to this Agreement, the Avoidance Claim shall be
        deemed recovered by Response for its bankruptcy estate pursuant to
        Bankruptcy Code Section 550, upon payment of the Purchase Price.

                                       5
<PAGE>

     5. Payments of the Purchase Price.

        (a) Payments at Closing. The Purchase Price [subject to credits toward
payment of the Purchase Price to which Hem-Onc is entitled, as set forth herein,
including, if applicable, in accordance with Section 6(b) below if the Final
Reconciliation (as defined therein) is completed as of Closing], shall be paid
as follows:

                (i) at Closing, Hem-Onc will assume the then aggregate
        outstanding capital lease obligations of Response to "Trimarc" and "GE
        Medical" under the capital leases described on Schedule 1 (each a
        "Capital Lease" and, collectively, the "Capital Leases"), by and between
        Response and Trimarc Financial, Inc. and GE Medical Systems, Inc.
        Hem-Onc will receive a credit at Closing towards the payment of the
        Purchase Price equal to the then outstanding principal balance due and
        payable under the Capital Leases (solely with respect to the leased
        equipment subject thereto which is or are included within the Purchased
        Assets); provided, that, if for any reason the Capital Leases (or either
        of them) (or Response's interest under either Capital Lease to the
        leased equipment included within the Purchased Assets), cannot be
        assigned, then Response shall pay, in full, at or before Closing, all
        amounts due under the affected Capital Lease and, in such event, Hem-Onc
        shall not receive a credit towards payment of the Purchase Price with
        respect to its assumption of the affected Capital Lease; and

                (ii) the balance of the Purchase Price (as determined after
        consideration of all other credits toward payment of the Purchase Price
        contemplated herein) shall be paid, in cash or immediately available
        funds, at Closing. As part of this payment of the balance of the
        Purchase Price (and not as an additional payment), Hem-Onc shall
        wire-transfer to AmSouth Bank, as Agent for the Banks (including
        AmSouth), an amount equal to the balance of the Purchase Price payable
        pursuant to this Section 5(a)(ii), less the $476,605.50 payment of the
        Avoidance Claim, and less the funds to be escrowed by Response in
        accordance with Sections 5(c) and 7 below; provided, that, such escrowed
        funds, to the extent payable from escrow to Response, shall also be
        wire-transferred to AmSouth in accordance with Sections 5(c) and 7 below
        at the time or times and to the extent such escrowed funds are otherwise
        required to be disbursed to Response (as set forth in said sections).
        Notwithstanding anything to the contrary in this Agreement, the full
        Avoidance Claim payment shall be made directly to Response.

        (b) Response Payments. If, as of Closing, the aggregate credits toward
payment of the Purchase Price to which Hem-Onc is entitled, as provided herein
[including credits pursuant to Section 5(a)(i) above and Section 6(b) below if
the Final Reconciliation described in Section 6 below is completed as of
Closing] exceeds the Purchase Price, then at Closing, Response shall be
obligated to pay Hem-Onc, in cash or immediately available funds, an amount
equal to the excess of such aggregate credits over the Purchase Price.

        (c) Escrow. If, as of Closing, the Final Reconciliation required by
Section 6 below is not completed, then out of the cash proceeds payable to
Response at Closing by Hem-Onc, Response shall be obligated to escrow (the
"Response Escrow"), with an escrow agent

                                       6
<PAGE>

mutually acceptable to Response and Hem-Onc, and Hem-Onc shall separately
deposit in escrow (the "Hem-Onc Escrow") with an escrow agent mutually
acceptable to Hem-Onc and Response, such amounts as are mutually agreeable to
the parties based on the adjustments that would have been made if Closing had
occurred on January 31, 2002. The monies so escrowed shall be retained in escrow
after Closing pending completion of and agreement to the Final Reconciliation as
required by Section 6. If, as a result of the Final Reconciliation, Response
shall be obligated to refund or pay monies to Hem-Onc or Hem-Onc shall be
obligated to pay an additional amount to Response, then, upon written notice of
such determination to the applicable escrow agent by either Response or Hem-Onc,
as the case may be, such escrow agent, subject to the last sentence of this
Section 5(c), shall disburse, from the escrow created by the party obligated to
make such payment to the other party the amount such party is obligated to pay
pursuant to Section 6(b) below (or, shall disburse to the other party all funds
held in such escrow if less than the amount due). After such disbursement, the
balance of the monies held in the paying party's escrow, if any, subject to the
last sentence of this Section 5(c), shall be disbursed to such party. Upon
completion of and agreement to the Final Reconciliation, the party (the
"Non-Paying Party") not obligated to make a payment to the other party, as set
forth in Section 6(b) below, shall be immediately entitled to all monies held in
the Non-Paying Party's escrow, subject to the last sentence of this
subparagraph. Each of Response and Hem-Onc shall be separately responsible for
the fees and costs of the escrow agent for each party's escrow and all costs of
creating, maintaining and terminating the same. All monies, if any, required to
be disbursed to Response in accordance with the foregoing from the Response
Escrow or the Hem-Onc Escrow shall, at the time or times such monies are
otherwise required to be disbursed to Response, be wire-transferred directly to
AmSouth, as Agent for the Banks (including AmSouth).

        (d) Prorations. Rents, telephone charges, personal property taxes,
employee wages, salaries and benefits and all other comparable expenses
reasonably capable of prorations, including Accrued Clinic Expenses payable by
Hem-Onc after Closing, as provided herein, shall be prorated as of the Closing
Date. To the extent any proratable items are unknown as of Closing, the parties
shall make their best estimate of such items at Closing. To the extent Closing
prorations are based on estimated expenses, no post-Closing re-prorations shall
be made should the actual amount of such estimated items vary from the amounts
estimated, unless otherwise expressly agreed, in writing, by the parties.
Notwithstanding the foregoing to the contrary, Response shall not be entitled to
a proration credit with respect to its payment, before Closing, of any expense
of Hem-Onc relating to the period after the Closing Date, if payment of such
expense is taken into account in the Final Reconciliation pursuant to Section
6(a)(iii) below. Similarly, Hem-Onc shall not be entitled to a proration credit
with regard to its payment, before or after Closing, of any item of expense of
Response relating to the period on or before Closing if and to the extent that
had Response paid such item of expense before Closing, such payment would have
been taken into account in the Final Reconciliation pursuant to Section
6(a)(iii) below.

        (e) Payment of Post-Petition Accrued Clinic Expenses.

                (i) Hem-Onc agrees to pay after Closing, all post-petition
        Accrued Clinic Expenses (as defined below) outstanding as of Closing.
        For this purpose and for

                                       7
<PAGE>

        purposes of the Final Reconciliation, a post-petition "Accrued Clinic
        Expense" means a post-petition, Clinic Expense (as otherwise defined in
        the Service Agreement), which is accrued, but unpaid, as of the Closing
        Date, and which is allowed as an administrative claim in Response's
        bankruptcy proceeding or which would have been allowed as an
        administrative claim in Response's bankruptcy proceeding, but for
        Hem-Onc's agreement to pay the same after Closing. In no event shall a
        post-petition "Accrued Clinic Expense" include any interest charge,
        fine, penalty or damages payable with respect to a valid post-petition
        Clinic Expense as a result of a payment or performance breach by
        Response prior to Closing (under any agreement or arrangement to which
        Response is a party). Further, Hem-Onc's agreement to pay any
        post-petition Accrued Clinic Expense after Closing is also predicated on
        either Hem-Onc's knowledge, as of Closing, of the amounts due and owing,
        the payment terms and the name and address of the applicable payees with
        respect thereto, or Hem-Onc's receipt of a written list or written
        record, at a reasonable time prior to the date any such expense is due,
        setting forth, at a minimum, the amounts due and owing, the payment
        terms and the name and address of the applicable payee with respect
        thereto (including the date such expense would first become past due or
        the first date on which, if such expense were not paid, a payment
        default with respect to such expense would exist, whether with the
        passage of time, the giving of notice or both, or otherwise). For this
        purpose, "knowledge" of any of the Terminated Employees (as defined
        below) employed by Hem-Onc immediately after Closing shall be deemed to
        be the knowledge of Hem-Onc. In addition, in no event shall Hem-Onc pay
        post-petition Accrued Clinic Expenses which consist of accrued payroll,
        bonuses, vacation and other benefits to which the Terminated Employees
        (as defined herein) are entitled as of Closing, or payroll or other
        taxes payable after Closing with respect thereto, unless the Terminated
        Employees to which such expenses relate are employed by Hem-Onc
        immediately following Closing.

                (ii) Hem-Onc shall be entitled to a credit towards payment of
        the Purchase Price for those, and only for those post-petition Accrued
        Clinic Expenses which it pays after Closing to the extent accrued and
        outstanding before January 1, 2002 (including paid vacation leave for
        those Terminated Employees employed by Hem-Onc immediately after Closing
        to the extent accrued while employed by Response before January 1,
        2002), but only to the extent such expenses are included within the
        Settlement Amounts or in any Service Fee paid before January 1, 2002.

        (f) Closing Date and Place/Closing Deliveries. Schedule 5(f) attached
hereto sets forth the date and place of Closing and the deliveries of the
respective parties at Closing.

     6. Payment Reconciliation.

        (a) Final Reconciliation. In order to calculate whether the payments
made by Hem-Onc to Response on and after January 1, 2002 and before Closing,
considering all payments made to Response by Hem-Onc pursuant to the Service
Agreement, as modified hereby during the Reconciliation Period, equals, exceeds
or are less than the aggregate amounts to which Response is entitled for such
period pursuant to Section 2(b) above, the parties agree to perform a final
reconciliation (the "Final Reconciliation") in accordance with the following
formula as of Closing or, if the information necessary to do the following
calculation is not

                                       8
<PAGE>

available as of Closing, as soon thereafter as is possible, but not later than
seven (7) business days after the Closing Date. The Final Reconciliation shall
be made in accordance with the following formula:

                (i) take the sum of all collections relating to Practice
        Revenues (as defined in the Service Agreement) of Hem-Onc or any other
        funds of Hem-Onc which are transferred or paid to Response or deposited
        in, transferred or swept to any bank account of Response at any time
        during the Reconciliation Period (the "Cash Collections"); add

                (ii) $64,108.40 (representing 100% of the Clinic Expenses
        incurred or accrued, but unpaid as of December 31, 2001, and with
        respect to which Response has been paid at or before Closing); subtract

                (iii) the sum of the post-petition Clinic Expenses (whether
        accrued on or before or after December 31, 2001), Physician Expenses and
        Capital Expenditures actually paid by Response for or on behalf of
        Hem-Onc during the Reconciliation Period [provided that Response is
        entitled to reimbursement for such Physician Expenses or Capital
        Expenditures in accordance with the terms of Section 2(b) above];
        subtract

                (iv) the Monthly Fee actually paid or due Response for all
        months (or partial months) during the Reconciliation Period, as
        described in Section 2(b) above (such Monthly Fee to be prorated for the
        month in which Closing occurs, if Closing is on or before April 1,
        2002); and subtract

                (v) the Accrued Clinic Expenses, as of the Closing Date, which
        have been not previously paid and which are not to be paid by Hem-Onc
        after Closing, but only to the extent allowable as an administrative
        claim in Response's bankruptcy proceeding, and cash equal to such
        Accrued Clinic Expenses is escrowed by Response, at Closing, in
        accordance with the terms of Section 7 below.

        (b) Reconciliation Payments/Payment Credits. Subject to Section 6(c)
below, to the extent the formula described in Section 6(a) above yields a
positive number, such amount shall represent an overpayment by Hem-Onc to
Response of the aggregate amounts otherwise due Response pursuant to Section
2(b) above, and Response shall remit to Hem-Onc not later than three (3)
business days following completion of the Final Reconciliation, in cash or
immediately available funds, an amount equal thereto; provided, that if the
Final Reconciliation is agreed to and completed as of Closing, then in lieu of
such payment by Response after Closing, Hem-Onc shall be entitled to a credit
towards payment of the Purchase Price at Closing equal to such positive amount.
If this formula yields a negative number, such negative number represents
Hem-Onc's underpayment of the aggregate amounts due Response pursuant to Section
2(b) above, and Hem-Onc shall remit to Response an amount equal thereto, not
later than the third business day following completion of the Final
Reconciliation, which amount shall be paid by wire by Hem-Onc directly to
AmSouth Bank, as Agent for the Banks (including AmSouth); provided, that if the
Final Reconciliation is completed and agreed to as of Closing, such payment by
Hem-Onc shall be made at Closing.

                                       9
<PAGE>

        If the Final Reconciliation is completed and agreed to after the Closing
Date, then the party obligated to remit a sum to the other party, as provided
above, shall cause the escrow agent of such party's escrow established in
accordance with Section 5(c) above to promptly disburse to the other party (or,
in the case of disbursements to Response, by wire to AmSouth as Agent for the
Banks), not later than the first business day after completion of and agreement
to the Final Reconciliation, an amount equal to the sum so required to be paid
(or all of the monies in such party's escrow if less than such required
payment), and such party shall be obligated to pay the remaining balance, if
any, to the other party (or, in the case of payments to Response, shall be paid
by Hem-Onc by wire to AmSouth, as Agent for the Banks) within three (3) business
days following completion of the Final Reconciliation, subject to the last
sentence of Section 5(c) below.

        (c) Dispute Resolution. If the parties cannot agree upon the Final
Reconciliation within three (3) business days from the completion of the Final
Reconciliation, then Response's designated independent accountant and Hem-Onc's
designated independent accountant shall each designate an independent accountant
and the two independent accountants so designated shall select a third
independent accountant; the final determination of the items in dispute shall be
made by a majority decision of the three independent accountants so selected.
The three accountants selected shall each be a certified public accountant, who
have not (and whose firm has not) previously been engaged by either party or any
affiliates thereof, unless agreed by both parties. In the absence of missing or
undisclosed relevant financial information, the decision of the three
independent accountants will be final and binding and not subject to review of
any kind. The expense of the outside independent accountants' review shall be
split equally by the parties. Only the items that are in dispute shall be
subject to evaluation and determination by the three independent accountants.
Once the items in dispute have been so resolved, the parties shall promptly
agree upon the Final Reconciliation, consistent with the party's agreement as to
the undisputed items and the decision of the three independent accountants on
the disputed items.

        (d) Purpose of Reconciliation. The parties acknowledge and agree that
the Final Reconciliation or the items described therein, is being calculated on
a cash basis and that for purposes of calculating the Final Reconciliation, the
various components of the foregoing calculation [excluding Section 6(a)(ii) and
Section 6(a)(v) above] will be calculated on a cash basis consistent with the
payment obligations of Hem-Onc to Response described in Section 2(b) above,
instead of the accrual method of accounting. In addition, the parties agree that
for the purposes of the foregoing calculation, post-petition Clinic Expenses
(incurred after December 31, 2001), Physician Expenses and Capital Expenditures
will be deemed paid once a check is processed and mailed by Response (or
wire-transfer is sent) relating to such expenses and such expenses will continue
to be the responsibility of Response after the Closing if such expenses are
included in the Final Reconciliation pursuant to Sections 6(a)(iii) or (v).

        For purposes of calculating the Final Reconciliation, Cash Collections
will include, in addition to all collections received and paid or transferred to
Response during the Reconciliation Period, any and all collections relating to
Practice Revenues which are associated with deposits in Hem-Onc's bank accounts
as of December 31, 2001, and which are paid or

                                       10
<PAGE>

transferred to Response or deposited or swept to a Response bank account on or
after January 1, 2002.

     7. Payment of Certain Expenses at or after Closing. Response acknowledges
and agrees that it shall be required to pay, in accordance with the payment
terms applicable thereto, after Closing, from the Purchase Price payable, in
cash or immediately available funds, to Response by Hem-Onc at Closing, all
allowed post-petition Accrued Clinic Expenses which Hem-Onc has not agreed to
pay after Closing. Response further acknowledges that it shall be required to
pay at or before Closing, or to set aside in escrow, the amount necessary to
satisfy all other expenses, obligations or liabilities, if any, of Response
incurred prior to Closing, if payment thereof is required in order to release,
as of Closing, any lien, claim or encumbrance on any of the Purchased Assets or
on any property of Hem-Onc, including the Accounts Receivable and proceeds paid
or payable with respect to the Accounts Receivable).

        Response agrees to escrow (the "Accrued Expense Escrow"), with an escrow
agent mutually acceptable to Response and Hem-Onc, out of the payments of the
Purchase Price made to Response at Closing by Hem-Onc, an amount equal to all
such post-petition Accrued Clinic Expenses described above (and which are to be
paid after Closing). The terms of the post-petition Accrued Expense Escrow shall
require the applicable escrow agent to pay, from the proceeds held in escrow,
all such Accrued Clinic Expenses when due or when directed by written notice
from either Response or Hem-Onc. To the extent that any of such post-petition
Accrued Clinic Expenses are not allowable as an administrative claim in
Response's bankruptcy proceeding or the obligation to pay the same is waived or
forgiven, and as a result Response is not obligated or permitted to pay the same
(in whole or in part), or the amount paid is less than the amount escrowed for
payment thereof, then the applicable escrow agent, upon receipt of written
notice of such event from either Response or Hem-Onc, shall promptly disburse to
Hem-Onc, out of the monies held in such escrow, an amount equal to such
post-petition Accrued Clinic Expenses which are not allowable as an
administrative claim in Response's bankruptcy proceeding or which otherwise
become non-payable (or an amount equal to the excess of the amount escrowed for
payment of any such expenses in excess of the amounts actually paid or due). If
after all such post-petition Accrued Clinic Expenses are paid in full (and after
disbursement to Hem-Onc of all escrowed funds to which it is entitled, as set
forth above), there remain proceeds in escrow, subject to the following, the
escrow agent shall disburse the remaining sums in escrow to Response. All
monies, if any, required to be disbursed in accordance with the above from the
Accrued Expense Escrow to Response shall, at the time or times such monies are
otherwise required to be disbursed to Response, be wire-transferred to AmSouth,
as Agent for the Banks (including AmSouth). Response shall be obligated to pay
all costs and expenses of the Accrued Expense Escrow, including all fees of the
applicable escrow agent related to the escrow, subject to bankruptcy court
approval. Hem-Onc agrees that Response's legal counsel, Akin, Gump, Strauss,
Hauer and Feld, LLP, may act as escrow agent for the Accrued Expense Escrow. For
the avoidance of doubt, the amounts to be escrowed pursuant to this Section 7
are not for payment of any pre-petition Clinic Expenses, and Hem-Onc and the
Stockholders waive (among other Claims) any claim for payment of unpaid
pre-petition Clinic Expenses.

                                       11
<PAGE>

     8. No Assumption of Liabilities. Except as expressly provided to the
contrary in this Agreement, Hem-Onc shall not assume or pay any indebtedness or
liabilities of Response, fixed or contingent, known or unknown (including Clinic
Expenses), which are incurred or accrued or are otherwise attributable to the
period on or prior to Closing (including any liabilities of Response arising
from a breach of any of the Assigned Contracts by Response at or before
Closing). Hem-Onc shall expressly assume at Closing, and thereafter pay and
perform, all payment and performance obligations of Response under the Assigned
Contracts (or the portion thereof which relate to Purchased Assets), to the
extent such obligations accrue or are attributable to the period after Closing.

     9. Mutual Releases.

        (a) Response's/LaMacchia's Releases. Upon and following Closing, each of
Response and LaMacchia, both individually and in LaMacchia's capacity as
President and Chief Executive Officer of Response, on behalf of each such party,
each such party's successors and assigns, and on behalf of any person claiming
by or through each such party, does hereby forever and absolutely release and
discharge Hem-Onc, the Stockholders and each of Hem-Onc's and the Stockholders'
directors, officers, shareholders, representatives, employees, agents, attorneys
and affiliates, including, but not limited to, any affiliated entities (the
"Affiliated Persons") from any and all claims, demands, losses, damages, causes
of actions or liabilities of any kind or nature, whether known or unknown, fixed
or contingent, filed, unfiled or scheduled (collectively, the "Claims"), that
Response or LaMacchia now has or may have ever had from the beginning of the
world to Closing against Hem-Onc, the Stockholders or any Affiliated Persons of
Hem-Onc or the Stockholders, including, but not limited to, any preference or
avoidance claims or any claim attributable to a violation of the automatic stay
or arising out of or relating to the Bankruptcy Case, excluding only those
Claims which Response or LaMacchia may have against Hem-Onc or the Stockholders
arising out of or attributable to a breach of any provisions of this Agreement.

        (b) Hem-Onc's/Stockholders' Releases. Upon and following Closing,
Hem-Onc and each Stockholder, both individually and in each Stockholder's
respective capacities as officer or director of Hem-Onc, on behalf of each of
such party, each such party's successors and assigns, and on behalf of any
person claiming by or through each such party, does hereby forever and
absolutely release and discharge Response, LaMacchia (both individually and in
his capacity as a Response officer and director) and each of Response's and
LaMacchia's Affiliated Persons from any and all Claims that Hem-Onc or any of
the Stockholders now has or may have ever had from the beginning of the world to
Closing against Response, LaMacchia or any Affiliated Persons of Response or
LaMacchia, excluding only those Claims which Hem-Onc or any of the Stockholders
may have against Response or LaMacchia arising out of or attributable to a
breach of any provisions of this Agreement.

        (c) Dismissal of Suits. At Closing, each of Hem-Onc and the
Stockholders, individually, on one hand, and Response and LaMacchia,
individually, on the other hand, to the extent applicable, shall dismiss with
prejudice the Adversary Proceeding and all claims against the opposite parties
raised or which could have been raised or filed by the parties thereof in
connection therewith, and any other adversary proceedings, contested matters,
suits or other actions that any such parties have brought as of Closing, could
have brought as of Closing or can

                                       12
<PAGE>

bring at or prior to Closing against any such opposite parties (or against any
such opposite parties' Affiliated Persons).

    10. Certain Covenants of the Parties/Court Approval.

        (a) Termination of Employment.

                (i) As of Closing, Response shall terminate the employment of
        all of its personnel who physically provide services to Hem-Onc, on
        behalf of Response, in accordance with the Service Agreement, at
        Hem-Onc's medical facilities in Florida (individually, a "Terminated
        Employee" and, collectively, the "Terminated Employees"). Hem-Onc and
        the Stockholders acknowledge their present expectation to employ
        immediately after Closing all or substantially all of the Terminated
        Employees, however, Response acknowledges that Hem-Onc shall have no
        obligation to hire any specific Terminated Employee.

                (ii) Prior to Closing, Hem-Onc and the Stockholders agree to use
        their reasonable efforts to cause all of the Terminated Employees who
        Hem-Onc offers to employ immediately after Closing to waive any claims
        that such employees have or may have against Response for severance
        benefits or otherwise, pursuant to a "Release" in form and content
        determined and prepared by Response; provided, that, neither Hem-Onc nor
        the Stockholders shall have any liability to Response if any such
        waivers are not given. Hem-Onc agrees to assume with respect to all of
        the Terminated Employees employed by Hem-Onc immediately after Closing,
        all of such Terminated Employee's unused, paid vacation leave (as of
        Closing) accrued while employed by Response in an amount not in excess
        of the aggregate amount set forth in Attachment 12(c)-I(g) attached to
        Schedule 12(c); provided, that Hem-Onc shall receive a credit towards
        payment of the Purchase Price in an amount equal to the dollar amount of
        any such unused vacation leave which accrued before January 1, 2002, to
        the extent included within the Settlement Amounts or in any Service Fee
        paid before January 1, 2002.

                (iii) Response agrees that as of Closing, all non-compete and
        non-solicitation obligations and covenants, if any, of Hem-Onc or the
        Terminated Employees hired by Hem-Onc after Closing shall terminate and
        be of no further legal force or effect.

        (b) Bankruptcy Court Approval.

                (i) Hem-Onc and the Stockholders acknowledge that, as a
        condition for closing on the transactions contemplated herein, the
        consent of the Bankruptcy Court must be obtained. Towards that end,
        Hem-Onc, Response and, by execution of a copy of this Agreement, the
        Banks hereby agree that they shall take any and all actions as may be
        reasonably necessary or desirable to cause the Bankruptcy Court to
        consider and approve the transactions contemplated herein at a hearing
        to approve the same scheduled for March 29, 2002 (as the same may be
        rescheduled by mutual written agreement of Hem-Onc and Response). In
        furtherance thereof, promptly following execution of this Agreement by
        all parties hereto, Response shall submit or cause to be submitted to
        the

                                       13

<PAGE>

        Bankruptcy Court, as a supplement to the motion Response previously
        filed for approval of the transactions contemplated by this Agreement, a
        copy of this Agreement and the schedules hereto.

                (ii) If the Bankruptcy Court does not approve this Agreement
        substantially in accordance with its terms, or affirmatively rejects
        this Agreement, then this Agreement shall automatically terminate upon
        the occurrence of such event (collectively "Court Rejection"), unless
        otherwise agreed by Hem-Onc and Response, in writing. Further, if the
        Bankruptcy Court has not yet ruled on the motion to approve this
        Agreement by April 30, 2002 or if the Bankruptcy Court's prior approval
        of this Agreement has been appealed and remains on appeal as of April
        30, 2002 (collectively "April 30th Status"), then either party may
        terminate this Agreement at any time after April 30, 2002, upon delivery
        of written notice to other party; provided, that, neither Response nor
        Hem-Onc, as the case may be, shall be permitted to so terminate this
        Agreement if such failure to approve this Agreement by April 30, 2002,
        or the appeal of this Agreement which remains in effect as of April 30,
        2002, arises from a breach by either party of the foregoing terms of
        this Section 10(b) or a breach by Response of Sections 3 or 13 hereof,
        or results from any willful action or inaction of such party designed to
        delay the approval of this Agreement. Upon termination of this
        Agreement, all terms of the Service Agreement, if any, that have been
        altered by this Agreement shall be reinstated in full force and effect
        as of January 1, 2002.

                (iii) The Banks shall have the right to withdraw their consent
        to and approval of this Agreement in the event of a Court Rejection or
        if the April 30th Status materializes, unless the Court Rejection or
        April 30th Status arises from the Banks' failure to support the
        transactions contemplated herein or the Banks' failure to support
        approval by the Bankruptcy Court of this Agreement, as otherwise
        required herein. Notwithstanding anything herein to the contrary, if the
        Banks breach their agreement to actively support the transactions
        contemplated herein or the Bankruptcy Court's approval of this
        Agreement, as described herein, then Hem-Onc shall have the right to
        terminate this Agreement by delivery of written notice to Response and
        the Banks.

                (iv) Notwithstanding anything herein to the contrary, Hem-Onc
        and Response agree that until the Bankruptcy Court approves this
        Agreement and the transactions contemplated hereby, if either Hem-Onc or
        Response shall be in breach of this Agreement, the other party shall
        have the unilateral right, exercisable by delivery of written notice to
        the breaching party to terminate this Agreement, without penalty.

    11. Management of Medical Practice. Subject to the terms set forth herein,
the parties hereto acknowledge and agree that from the date of this Agreement
through Closing, Response shall continue to manage and administer Hem-Onc's
medical practice, and shall continue to provide the other services required
under the Service Agreement (as hereby modified), pursuant to and in accordance
with the Service Agreement, consistent with past practices; and that Hem-Onc and
the Stockholders shall reasonably cooperate with Response, and Response shall
reasonably cooperate with Hem-Onc and the Stockholders, as called for in this
Agreement, and continue to operate Hem-Onc's medical practice in the ordinary
course. In this regard, Response

                                       14
<PAGE>

acknowledges that by virtue of the revisions to the Service Fee in accordance
with Section 2(b) above applicable to the Reconciliation Period, Hem-Onc and the
Stockholders are effectively assuming the full risk of loss to the Purchased
Assets and all risks of Hem-Onc's medical practice through Closing. As such,
Response agrees that from the date of this Agreement through Closing, in
carrying out its duties pursuant to the Service Agreement, as modified herein,
Response shall reasonably consult and cooperate with Hem-Onc and the
Stockholders and abide by the reasonable directions of Hem-Onc and the
Stockholders, so long as the same does not violate the provisions set forth in
this Section 10(c).

        (a) Response's Covenants. In connection with the foregoing, Response
expressly agrees that, without the prior written consent of Hem-Onc or the
Stockholders, until Closing (or, if sooner, until termination of this
Agreement), Response shall not:

                (i) advance additional monies to or on behalf of Hem-Onc out of
        the ordinary course of business, as established by past practice;

                (ii) acquire any additional property or equipment, except for
        the replacement of obsolete tangible personal property in the ordinary
        course, consistent with past practices and the terms of the Service
        Agreement; provided, that, Response shall not replace or purchase any
        additional laboratory or pharmacy supplies (other than what is on hand
        as of the date of this Agreement), except as directed, in writing, by
        the Stockholders [so long as such directions do not violate Section
        11(b) below]; and provided, further, that Response shall not acquire any
        tangible personal property with a cost in excess of $10,000, or any
        tangible personal property (excluding tangible personal property
        acquired before the date of this Agreement), the cost of which, when
        added to all other tangible personal property acquired on or after
        January 1, 2002, exceeds $20,000, unless authorized, in writing, by the
        Stockholders;

                (iii) pledge or encumber any of the Purchased Assets or incur
        any indebtedness or obligations which are or will be secured by a lien
        on any of the Purchased Assets or on any assets of Hem-Onc, other than
        property that is already pledged or encumbered;

                (iv) sell, transfer or dispose of any of the Purchased Assets
        without the prior written consent of Hem-Onc, except for the sale,
        transfer or disposal of pharmacy and laboratory supplies and inventory
        sold or consumed in the ordinary course, consistent with past practices,
        and in accordance with the terms of the Service Agreement;

                (v) execute, after the date of this Agreement, any new
        contracts, leases or agreements with respect to Hem-Onc's medical
        practice or renew, extend, amend, modify, sign or pledge any existing
        contracts, leases and agreements included with the Assigned Contracts
        (or which, if in existence as of Closing, would be within the Assigned
        Contracts), other than the pledge of contracts, leases and agreements
        already pledged or collateralized; or

                                       15
<PAGE>

                (vi) alter the rate or basis of compensation paid to any of
        Response's employees who provide services to Hem-Onc, on behalf of
        Response, at Hem-Onc's facilities in Florida.

                In addition, Response agrees to use its reasonable efforts to
        maintain all contractual arrangements with respect to Hem-Onc's medical
        practice in effect as of February 27, 2002, and shall maintain all
        insurance obtained or maintained with respect to any assets or property
        used or held for use exclusively in Hem-Onc's medical practice, to the
        extent in place as of February 27, 2002. Response also agrees to direct
        or instruct its employees rendering services on Response's behalf at
        Hem-Onc's facility or facilities, to abide by the instructions and
        directions of the Stockholders with respect to the billing of services
        rendered by Hem-Onc and the collection of fees for services rendered and
        goods sold; provided, that, such instructions or directions do not
        violate the provisions of Section 11(b) below.

        (b) Hem-Onc's/Stockholders' Covenants. In connection therewith, Hem-Onc
and Stockholders expressly agree that, without the prior written consent of
Response, until Closing (or, if sooner, until termination of this Agreement),
Hem-Onc and the Stockholders shall not:

                (i) fail to remit payments of all components of the Service Fee
        [as modified for the Reconciliation Period in accordance with Section
        2(b) above] to Response consistent with past practices and the terms of
        the Service Agreement;

                (ii) alter their ordinary course, historical pattern of conduct
        in collecting and attempting to collect Accounts Receivable (unless such
        different conduct is intended to result in an overall increase in
        collections of outstanding Accounts Receivables);

                (iii) alter their ordinary course, historical pattern of conduct
        in billing for services rendered (including but not limited to physician
        and ancillary services);

                (iv) materially increase the historical patterns of the
        pharmaceuticals and supplies which they request Response to purchase
        (and shall not request extraordinary or unusual amounts of
        pharmaceuticals);

                (v) alter their ordinary course, historical pattern of conduct
        in hours of work or in treating patients (including but not limited to
        the number, type and financial ability of patients, and use of ancillary
        services); or

                (vi) approve, implement or make any capital expenditure without
        the written approval of Response.

    12. Conditions of Closing. Closing on the purchase and sale of the Purchased
Assets is subject to satisfaction (or waiver by the adversely affected party) of
each of the following:

                                       16
<PAGE>

        (a) Compliance with Covenants of Parties. Each of the parties hereto
(and the Banks, with respect to its agreement set forth herein) shall have
performed or complied in all material respects with all covenants and agreements
of each such party required to be performed or complied by each such party under
this Agreement at or prior to Closing.

        (b) Approval of Agreement. The approval of this Agreement and the
transactions contemplated hereby by the Bankruptcy Court.

        (c) Representations and Warranties of the Parties. The representations
and warranties of Response or Hem-Onc, as the case may be, as set forth on
Schedule 12(c) attached hereto, shall be true and correct as of the date of this
Agreement and shall be true and correct in all material respects as of the
Closing Date, with the same force and effect as if such representations and
warranties had been made at and as of the Closing Date.

        (d) New Leases for Certain Purchased Assets. If any of the Purchased
Assets which are leased by Response are the subject of a lease which includes
property in addition to such leased Purchased Assets, Hem-Onc shall have entered
into an agreement for the lease of such leased Purchased Assets with the
applicable lessor thereof, on terms and conditions substantially similar to
those applicable to Response's lease thereof immediately before Closing.

    13. No Bids. Response represents that prior to the date of this Agreement,
the bidding terminated, in the Bankruptcy Case for the Service Agreement, the
Purchased Assets (or any of them) and Response's rights in and to the Service
Agreement and all of such items were withdrawn from the auction of Response's
assets otherwise proposed in connection with the Bankruptcy Case. Response
hereby agrees that, from the date of this Agreement to Closing (or, if sooner,
until termination of this Agreement), it shall not accept or solicit any bids or
offers from any party for the Service Agreement, any of the Purchased Assets or
any of Response's rights in and to the Service Agreement. To the extent not
previously performed, upon execution of this Agreement, Response shall promptly
disclose to all bidders or prospective bidders of its assets in the Bankruptcy
Case of the existence of this Agreement (without sharing the contents hereof
unless required by the Bankruptcy Court) and its intention to close on the
transactions contemplated hereby in accordance with the terms hereof. Response
and Hem-Onc, and by execution hereof, the Banks, further agree to support,
without reservation, the approval of this Agreement by the Bankruptcy Court. In
the event that the Bankruptcy Court does not approve this Agreement, or that any
order approving this Agreement is reversed or materially modified (unless such
modification is acceptable to Response and Hem-Onc): (i) this Agreement shall
not be binding on any party (provided, that the provisions of Sections 15, 16
and 17 below, and the obligations of the parties pursuant thereto, as well as
any liability of any party hereunder arising from a breach by any such party
before such event of any of the provisions of this Agreement, shall survive such
event and shall survive the termination of this Agreement, as the case may be);
(ii) no representation or warranty made in this Agreement shall be binding on
any party; and (iii) Response, Hem-Onc, the Stockholders and the Banks shall
each be free to take any action permissible under law or equity with respect to
the Purchased Assets, the Service Agreement and all other areas or items
addressed herein, including a renewal of a bidding process and proposed auction
for those items.

                                       17

<PAGE>

    14. Access to Records.

        (a) Hem-Onc Access. At all times following the date of this Agreement
and up to Closing (or, if sooner, until the termination of this Agreement), in
furtherance of Hem-Onc's acquisition of the Purchased Assets and the termination
of the Service Agreement, Response agrees to provide Hem-Onc, and its legal,
accounting and financial representatives, access to and, if requested, copies of
such of Response's books, records, documents and information, including
contracts, leases and agreements, to the extent they relate to the Purchased
Assets or Hem-Onc's medical practice, as Hem-Onc may reasonably request, from
time to time, except as to those excluded from Section 1(d) above. All costs
incurred in connection therewith by Hem-Onc or any of its representatives, shall
be borne solely by Hem-Onc.

        (b) Response Access. Hem-Onc already possesses and owns all clinical
records of its and its physicians' patients, including all patients treated at
the Impact Center in Port St. Lucie, Florida. After Closing, Response or its
successor shall have such reasonable access to all records within Hem-Onc's or
the Stockholders' control or possession as is reasonably required for purposes
of the administration of its bankruptcy estate, or as otherwise reasonably
needed, subject to applicable laws or the provisions of any agreement to which
Hem-Onc is subject to, including laws restricting access to confidential patient
information. All costs incurred in connection therewith by Response or any of
its representatives shall be borne solely by Response.

    15. Payment of Costs by Parties. Each party will be responsible for its own
legal, accounting and other expenses incurred in connection with this Agreement
and the transactions contemplated herein.

    16. Public Announcement/Confidentiality. Each of Hem-Onc and Response and,
by execution hereof, the Banks agree that neither such party, nor each such
party's Affiliated Persons, including each such party's attorneys and
accountants, shall disclose the existence or content of this Agreement to any
person (including disclosures to the public and disclosures to any person making
or seeking to make or who is in a position to make a competing offer or bid for
the Purchased Assets or Response's interest in the Service Agreement), other
than disclosures reasonably necessary in connection with the Bankruptcy Case
(including, without limitation, disclosures to unsecured creditors of Response,
and disclosures to the United States Trustee), without the prior written consent
of both Hem-Onc and Response. Notwithstanding the foregoing, any disclosures
required by law, or necessary to complete the transactions contemplated by this
Agreement or necessary to enforce any such party's rights hereunder may be made
without the need for either party's consent. It is the specific intent of the
parties hereto that in no event shall the contents of this Agreement be used by
Response or any of its representatives, directly or indirectly, as support for
or in formulating a competing offer or bid by any party for any of Response's
assets, including the Purchased Assets or Response's interest in the Service
Agreement.

    17. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida. Any and all disputes that may
arise with respect to this Agreement [excluding disputes concerning the
computation of the Final

                                       18
<PAGE>

Reconciliation, which disputes are to be resolved in accordance with Section
6(c) above] shall be adjudicated by the Bankruptcy Court to the extent that its
jurisdiction permits, and neither party shall object to the jurisdiction of the
Bankruptcy Court to hear such disputes or to its jurisdiction over their person.
Response and Hem-Onc each shall have the right to seek enforcement of the other
party's respective obligations to close on the transactions hereby contemplated
by action for specific performance, injunction or other equitable relief filed
with the Bankruptcy Court, if the other party shall be in breach of such other
party's obligations with respect thereto. If the jurisdiction of the Bankruptcy
Court does not permit it to adjudicate any such equitable action, then either
party shall have the right to file an action for specific performance,
injunction or other equitable relief with any other court of competent
jurisdiction in the event of any such breach by the other party.

    18. Banks' Approval. This Agreement shall not be effective until approved by
AmSouth Bank, Bank of America, N.A., and Union Planters Bank, N.A.
(collectively, the "Banks"), through the Banks' agent, AmSouth Bank. In this
regard, it is the expectation of the parties that this Agreement shall be
executed simultaneously by all parties hereto, and the Banks, through AmSouth.

    19. Miscellaneous.

        (a) Survival. Upon the termination of this Agreement in accordance with
the express terms hereof, all of the obligations of the parties set forth herein
shall automatically terminate; provided, that the provisions of Sections 15, 16
and 17 hereof and obligations of the parties pursuant thereto, as well as any
liability of any party hereunder arising from a breach by any such party before
termination of any of the provisions of this Agreement, shall survive the
termination of this Agreement. Upon Closing, the representations and warranties
of the parties set forth in Schedule 12(c) shall only survive until the
completion of and agreement to the Final Reconciliation and the payment of any
sums due thereunder pursuant to Section 6 above.

        (b) Further Actions. Before Closing, each party hereto shall use its
reasonable efforts to cause the transactions hereby contemplated to be
consummated and to cause each of the conditions applicable to each such party's
and the other party's obligations to close to be satisfied. In furtherance
thereof, Hem-Onc and Response agree to reasonably cooperate in securing the
assignment of the Capital Leases to Hem-Onc or to secure the release therefrom
of the leased Purchased Assets which is subject thereto, if either such Capital
Lease includes the lease of other equipment or property; and in such event, to
cause the applicable lessor with respect thereto to enter into a new lease
agreement with Hem-Onc at Closing for Hem-Onc's continued lease thereof after
Closing, on terms and conditions substantially similar to those applicable to
Response's lease of such equipment immediately before Closing. After Closing,
each party hereto shall execute and deliver such further instruments and take
such further actions as any other party hereto may reasonably request to effect,
consummate, confirm or otherwise evidence the transfer to Hem-Onc of the
Purchased Assets in accordance with the terms hereof or the other transactions
contemplated herein.

        (c) Amendments. This Agreement may only be amended by written instrument
signed by Hem-Onc and Response, and consented to by the Banks. No course of

                                       19

<PAGE>

dealing between or among any of the parties hereto any other persons having any
interest in this Agreement shall be deemed effective to modify, amend or
discharge any part of this Agreement or any rights or obligations of any party
hereto under or by reason of this Agreement.

        (d) Notices. All notices, demands and other communications to be given
or delivered under or by reason of the provisions of this Agreement shall be in
writing and shall be deemed to have been given when personally delivered, three
(3) days after deposit in the U.S. mail, if sent by registered or certified
mail, return receipt requested, postage prepaid and addressed as follows, the
next business day if sent by a nationally recognized overnight courier service
and addressed as follows, or upon receipt of electronic confirmation of delivery
if sent by facsimile to the respective parties' facsimile number as follows:

            If to Response or LaMacchia:

                     Response Oncology, Inc.
                     1805 Moriah Woods Boulevard
                     Memphis, Tennessee 38117
                     Attention: Anthony M. LaMacchia, President and CEO
                     Facsimile: 901-763-7045

            in each instance, with a copy to:

                     Akin, Gump, Strauss, Hauer and Feld, LLP
                     Robert S. Strauss Building
                     1333 New Hampshire Avenue--N.W.
                     Suite 400
                     Washington, District of Columbia 20036
                     Attention: James A. Barker, Jr., Esq./Sam J. Alberts, Esq.
                     Facsimile: 202-887-4288

            If to Hem-Onc or the Stockholders:

                     Hem-Onc Associates of the Treasure Coast, P.A.
                     1801 SE Hillmoor Drive
                     Suite B-101
                     Port St. Lucie, Florida 34952
                     Attention: Alan S. Collin, M.D., President
                     Facsimile: 561-335-5082

                                       20
<PAGE>

            and in each instance, with a copy to:

                     Dean, Mead, Minton & Klein
                     1903 South 25th Street
                     Suite 200
                     Fort Pierce, Florida 34947
                     Attention: Michael D. Minton, Esq./Joel C. Zwemer, Esq.
                     Facsimile: 561-464-7877

            If to the Banks:

                     AmSouth Bank, as Agent for the Banks
                     Special Assets Department
                     315 Deaderick Street, 8th Floor
                     Nashville, Tennessee 37237
                     Attention: John E. Adcox, Jr.
                     Title:     Vice-President
                     Facsimile: 615-736-6633

            and in each instance, with a copy to:

                     Waller, Lansden, Dortch & Davis, PLLC
                     Nashville City Center
                     511 Union Street, Suite 2100
                     Nashville, Tennessee 37219
                     Attention: Robert A. Guy, Esq./John C. Tishler, Esq.
                     Facsimile: 615-244-6804

        (e) Binding/Assignment. This Agreement and all of the provisions hereof
shall be binding upon and inure to the benefit of the parties hereto and their
respective heirs, legatees, personal representatives, successors and assigns,
but neither this Agreement nor any of the rights, interests or obligations
hereunder of any party shall be assignable without prior written consent of the
other parties.

        (f) Severability. Whenever possible, each provision of this Agreement
shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be prohibited
by or invalid under applicable law, such provision shall, to the extent the
omission of such provision will not materially alter the substantive terms of
this Agreement, be ineffective only to the extent of such prohibition or
invalidity, without invalidating the remainder of such provisions or the
remaining provisions of this Agreement.

        (g) No Third Party Beneficiaries. Nothing in this Agreement, whether
express or implied, is intended to confer any rights or remedies under or by
reason of this Agreement to any other persons other than the parties hereto and
their respective successors, permitted assigns, heirs, legatees and personal
representatives, as the case may be, nor is anything in this

                                       21
<PAGE>

Agreement intended to relieve or discharge the obligation or liability of any
third persons to any party, nor shall any provision give any third parties any
rights of subrogation or action over or against any party. This Agreement is not
intended to and does not create any third party beneficiary rights whatsoever.

        (h) No Strict Construction. The language used in this Agreement shall be
deemed to be the language chosen by the parties hereto to express their mutual
intent, and no rule of strict construction shall be applied against any party.

        (i) Captions. The captions used in this Agreement are for convenience or
reference only and do not constitute a part of this Agreement and shall not be
deemed to limit, characterize or in any way affect any provision of this
Agreement, and all provisions of this Agreement shall be enforced and construed
as if no caption had been used in this Agreement.

        (j) Complete Agreement. This Agreement, including the schedules and the
documents referred to herein, and that certain letter of intent, dated February
27, 2002, by and between the parties hereto and the Banks (to the extent not
replaced by or inconsistent with the terms hereof), contain the complete
agreement between the parties with respect to the subject matter hereof and
supersede any prior understandings, agreements or representations by or between
the parties, written or oral, which may have related to the subject matter
hereof in any way.

        (k) Counterparts. This Agreement may be executed in one or more
counterparts, all of which taken together shall constitute one and the same
instrument. Facsimile signatures will constitute original signatures for
purposes of this Agreement; provided that the parties shall promptly exchange
original signatures after the execution thereof.

        (l) Tax Allocation. The parties agree to allocate the Purchase Price
among the Purchased Assets and Settlement Amounts for federal income tax
purposes in accordance with the Purchased Assets' and Settlement Amounts'
relative "book" values as of December 31, 2001, as reflected on the Balance
Sheet; and shall make all necessary filings (including those required under
Internal Revenue Code Section 1060) in accordance with that allocation.

    20. Definitions. The following described terms shall be defined as set forth
in the following described sections of this Agreement (or otherwise as follows):

        (a) "Accrued Clinic Expense" is defined in Section 5(e).

        (b) "Accrued Expense Escrow" is defined in Section 7.

        (c) "Acquired Assets" is defined in Section 1(a).

        (d) "Adversary Proceeding" is defined in the fourth "Whereas" clause in
the Recitals section of this Agreement.

        (e) "Affiliated Persons" is defined in Section 9(a).

                                       22
<PAGE>

        (f) "April 30th Status" is defined in Section 10(b)(ii).

        (g) "Assigned Contracts" is defined in Section 1(b)(i).

        (h) "Assigned Prepayments" is defined in Section 1(c).

        (i) "Assigned Name" is defined in Section 1(e).

        (j) "Assigned Records" is defined in Section 1(c).

        (k) "Avoidance Claim" is defined in Section 4(b)(ii).

        (l) "Balance Sheet" is defined in Section 1(c).

        (m) "Bankruptcy Case" is defined in the third "Whereas" clause in the
Recitals section of this Agreement.

        (n) "Bankruptcy Court" is defined in the third "Whereas" clause in the
Recitals section of this Agreement.

        (o) "Bankruptcy Rules" is defined in Section 3.

        (p) "Banks" is defined in Section 18.

        (q) "Capital Expenditures" is defined in Section 2(b)(iii).

        (r) "Capital Lease" or "Capital Leases" is defined in Section 5(a)(i).

        (s) "Cash Collections" is defined in Section 6(a)(i).

        (t) "Claims" is defined in Section 9(a).

        (u) "Closing" is defined in Schedule 5(f), attached to this Agreement.

        (v) "Closing Date" is defined in Schedule 5(f), attached to this
Agreement.

        (w) "Court Rejection" is defined in Section 10(b)(ii).

        (x) "Final Reconciliation" is defined in Section 6(a).

        (y) "GAAP" is defined in Section 4(a).

        (z) "Hem-Onc" is defined in the opening paragraph to this Agreement.

        (aa) "Hem-Onc Escrow" is defined in Section 5(c).

                                       23
<PAGE>

        (bb) "LaMacchia" means Anthony M. LaMacchia.

        (cc) "Monthly Fee" is defined in Section 2(b)(iv).

        (dd) "Non-Paying Party" is defined in Section 5(c).

        (ee) "Overpayment" is defined in Section 5(b).

        (ff) "Purchased Assets" is defined in the last sentence of Section 1.

        (gg) "Purchase Price" is defined in Section 4.

        (hh) "Real Property Lease" or "Real Property Leases" is defined in
Section 1(b)(ii).

        (ii) "Reconciliation Period" is defined in Section 2(b).

        (jj) "Response" is defined in the first paragraph of this Agreement.

        (kk) "Response Escrow" is defined in Section 5(c).

        (ll) "Service Agreement" is defined in the first "Whereas" clause in the
Recitals section of this Agreement.

        (mm) "Settlement Amounts" is defined in Section 4(b)(i).

        (nn) "Stockholders" is defined in the first paragraph of this Agreement.

        (oo) "Terminated Employee" or "Terminated Employees" is defined in
Section 10(a)(i).

                                       24
<PAGE>

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the first date written above.

                                  "HEM-ONC"

                                  HEM-ONC ASSOCIATES OF THE TREASURE COAST, P.A.

                                  By: /s/ Alan S. Collin
                                      -------------------------------
                                      Alan S. Collin, M.D., President

                                  "STOCKHOLDERS"

                                  /s/ Alan S. Collin
                                  -----------------------------------
                                  Alan S. Collin, individually

                                  /s/ Nicholas O. Iannotti
                                  -----------------------------------
                                  Nicholas O. Iannotti, individually

                                  /s/ Paul M. Swanson
                                  -----------------------------------
                                  Paul M. Swanson, individually

                                  /s/ Michael S. Wertheim
                                  -----------------------------------
                                  Michael S. Wertheim, individually

                                  "RESPONSE"

                                  RESPONSE ONCOLOGY, INC.

                                  By: /s/ Anthony M. LaMacchia
                                      -------------------------------
                                      Anthony M. LaMacchia, President

                                  "LAMACCHIA"

                                  /s/ Anthony M. LaMacchia
                                  -----------------------------------
                                  Anthony M. LaMacchia, individually

                                       25
<PAGE>

        CONSENTED TO AND APPROVED THIS 15th DAY OF MARCH, 2002.

                                       AMSOUTH, AGENT TO BANKS
                                       (including AmSouth Bank)

                                       By: /s/ John E. Adcox, Jr.
                                           ----------------------------------
                                           John E. Adcox, Jr., Vice-President

                                       26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]